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ABSTRACT 
 
Secondary Structural and Functional Studies of Rotavirus NSP4 and Caveolin-1 Peptide-
Peptide Interactions. (December 2009) 
Megan Elizabeth Schroeder, B.A., Bellarmine University 
Chair of Advisory Committee: Dr. Judith M. Ball 
 
The rotavirus NSP4 protein is the first described viral enterotoxin.  Abundant 
data from our laboratory reveals that NSP4 binds both the N- and C-termini of caveolin-
1 (aa2-31 and 161-178, respectively).  Yeast two-hybrid and peptide binding analysis 
mapped the caveolin-1 binding site to three hydrophobic residues within the amphipathic 
-helix, enterotoxic peptide domain (aa114-135).  The research studies herein utilized 
peptides to investigate the interaction between NSP4 and caveolin-1.  Peptides were 
synthesized corresponding to the amphipathic -helix and caveolin-1 binding domain of 
NSP4 (aa112-140) and to the N- (aa2-20 and 19-40) and C- (161-178) termini of 
caveolin-1, and were utilized in structural and functional studies.  Fluorescence binding 
assays revealed that NSP4 (aa112-140)
 
binds to the N-terminus (aa19-40) of caveolin-1 
with a stronger affinity than the C-terminus (aa161-178).  In addition, this assay further 
delineated the NSP4 binding domain on caveolin-1 to aa19-40.  Secondary structural 
changes following NSP4-caveolin-1 peptide-peptide interactions were investigated by 
circular dichroism analysis.  Changes in -helix formation were observed only upon 
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interaction of the NSP4112-140 peptide with the C-terminal caveolin-1 peptide (C-Cav161-
178). 
The NSP4112-140 peptide contains a potential cholesterol recognition amino acid 
consensus (CRAC) sequence.  Therefore this peptide was examined for cholesterol 
binding.  Results of the binding assay revealed NSP4 binds cholesterol with a Kd of 7.67 
± 1.49nM and this interaction occurs via aa112-140.  Mutation of amino acid residues 
within the CRAC motif resulted in weaker binding affinities between each of the 
corresponding mutant peptides and cholesterol.   
NSP4 peptides containing mutations within the hydrophobic and charged faces of 
the amphipathic -helix, enterotoxic peptide and caveolin-1 binding domain of NSP4 
were examined for changes in secondary structure as well as diarrhea induction in mouse 
pups.  Circular dichroism analysis revealed that mutation of hydrophobic residues 
resulted in a decrease in -helix formation, whereas mutation of acidic and basic charged 
residues caused little to no change in -helical content.  When tested for diarrhea 
induction in mouse pups, the peptides containing mutations of either the hydrophobic or 
basic charged residues did not cause diarrhea.  Taken together, the results of this 
research suggest a complex interplay between NSP4 secondary structure, caveolin-1 and 
cholesterol binding and diarrheagenic function. 
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NOMENCLATURE 
 
aa Amino Acid 
AAH Amphipathic -helix  
A660/795 Absorbance 
[Ca2+]i   Intracellular Calcium 
 
cav-1   Caveolin-1 
 
CCD   Coiled Coil Domain 
 
CD   Circular Dichroism 
 
Cl-   Chloride 
 
C-MAD  C-Terminal Membrane Attachment Domain 
 
CRAC   Cholesterol Recognition/Interaction Consensus Sequence 
 
CSD   Caveolin Scaffolding Domain 
 
DIPCIDI  N,N’-diisopropylcarbodiimide 
 
DIPEA  N,N-diisopropylethylamine 
 
DLP   Double Layered Particle 
 
DOPS   1,2-dioleoyl-sn-glycero-3-[phosphor-L-serine] 
 
dsRNA  Double-Stranded RNA 
 
eIF4G   Eukaryotic Initiation Factor 4G 
 
ELISA   Enzyme-Linked Immunosorbent Assay 
 
ER   Endoplasmic Reticulum 
 
EU   Endotoxin Units 
 
  
ix
Fmax   Maximum Fluorescence  
 
Fmoc   Fluorenylmethoxycarbonyl 
 
FRET   Fluorescence Resonance Energy Transfer 
 
H2SO4   Sulfuric Acid 
 
HBTU   O-Benzotriazole-N,N,N’,N’-tetramethyluronium-hexafluoro- 
phosphate 
 
HCl   Hydrochloric Acid 
 
HOBt   1-hydroxy-benzotriazole 
 
HPLC   High Performance Liquid Chromatography 
 
kDa   Kilodalton 
 
Kd   Dissociation Constant 
 
LAL   Limulus Amebocyte Lysate 
 
LS   Light Scattering 
 
Mg(NO3)2  Magnesium Nitrate 
 
MALDI  Matrix-Assisted Laser Desorption/Ionization 
 
MOPS   3-morpholinopropanesulfonic Acid 
 
mt   Mutant 
 
N2   Nitrogen 
 
nM    Nanomolar 
 
N-MAD  N-Terminal Membrane Attachment Domain 
 
NMR   Nuclear Magnetic Resonance 
 
NSP   Non-Structural Protein 
 
NTP   Nucleotide Triphosphate 
  
x
 
OD   Oligomerization Domain 
 
PABP   Poly(A) Binding Protein 
 
PBS   Phosphate Buffered Saline 
 
PLC-IP3  Phospholipase C-inositol 1,4,5-triphosphate 
 
POPC   1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
 
PM   Plasma Membrane 
 
RV   Rotavirus 
 
SEC   Size Exclusion Chromatography 
 
SPPS   Solid Phase Peptide Synthesis 
 
ssRNA   Single-Stranded RNA 
 
SUV   Small Unilamellar Vesicles 
 
TFA   Trifluoroacetic Acid 
 
TFE   Trifluoroethanol 
 
TLC   Thin Layer Chromatography 
 
TLP   Triple Layered Particle 
 
TMD   Transmembrane Domain 
 
VP    Viral Protein 
 
wt   Wild Type 
 
Y131   Tyrosine 131 
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CHAPTER I 
INTRODUCTION: ROTAVIRUS, NON-STRUCTURAL PROTEIN 4 (NSP4), 
CAVEOLIN-1 AND THEIR INTERACTION 
 
Rotavirus 
As the major cause of severe gastrointestinal disease in children under the age of 
five, rotavirus (RV) infection is responsible for approximately 440,000 childhood deaths 
worldwide every year (1).  While most of these deaths occur in developing countries, 
primarily due to the lack of adequate medical care, the disease continues to be a problem 
in developed countries as well.   In the United States alone, RV infections result in 
400,000 doctor visits, 55,000-70,000 hospitalizations and 20-60 deaths each year (2).  
While infection occurs in all mammals and generally affects the young (< 5yrs) (3, 4), 
some studies have reported that RV infections occur in young adults, 
immunocompromised individuals and the elderly as well (5, 6).  The severe diarrhea that 
occurs in infected individuals is a result of fluid imbalance in the small intestine, which 
can lead to dehydration and eventually death without proper care (7).  Several reports 
indicate that rotavirus does not remain solely within the intestine, but can escape the 
gastrointestinal tract and be found in various organs (i.e. stomach, liver, lungs, kidneys, 
heart, pancreas and bladder), indicating that antigenemia and viremia occur during 
infection (8, 9, 10, 11). 
 
 
____________ 
This dissertation follows the style of Biochemistry. 
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RV is a nonenveloped RNA virus that belongs to the Reoviridae family of viruses.  
The viral genome is composed of eleven segments of double stranded RNA (dsRNA) 
which encode six structural proteins (VP1, VP2, VP3, VP4, VP6, VP7) and six non-
structural proteins (NSP1, NSP2, NSP3, NSP4, NSP5, NSP6).   Each protein is encoded 
by a single segment of RNA with the exceptions of NSP5 and NSP6, which are encoded 
by overlapping reading frames of a single genome segment (12).  Surrounding the 
segmented genome is a triple layered icosahedral capsid that is composed of three 
concentric protein coats.  The VP1, VP2 and VP3 structural proteins make up the inner 
core that contains the viral dsRNA.  The intermediate capsid surrounds the inner core and 
is composed solely of the VP6 structural protein.  The outer capsid is formed from the 
VP7 and VP4 structural proteins, the latter of which forms spikes on the surface of the 
virion (12, 13).  Figure 1A depicts the structure of the rotavirus virion and the proteins 
involved in each capsid layer.  Figure 1B is a western blot of each viral protein and their 
corresponding RNA segment.  Table 1 lists each viral protein and their function(s). 
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Figure 1: A. Cryo-EM Reconstruction of the Rotavirus Triple-Layer Particle Depicting the 
Structural Proteins.  The outer capsid is composed of VP-7 (yellow) and VP-4 (orange).  The middle 
capsid is composed of VP-6 (blue).  The inner capsid is composed of VP-2 (green). VP1 and VP3 (red) are 
transcriptional enzymes located within the inner core. Surrounding the transcriptional enzymes are the 
genome segments (RNA) which are shown as inverted conical spirals (14). B. Rotavirus Western Blot. 
Western blot of a simian rotavirus depicting the structural and nonstructural proteins and their 
corresponding RNA transcripts (14). 
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Table 1: Rotavirus Proteins and Their Functions (4, 12) 
Genome Segment: Rotavirus Protein: Description / Function / Location: 
1 VP1 Core capsid protein; RNA-
dependent RNA polymerase; located 
in the inner core 
2 VP2 Core capsid protein; RNA binding; 
required for replicase activity of 
VP1; located in the inner core 
3 VP3 Core capsid protein; 
Guanylytransferase and 
methyltransferase activity; RNA 
binding; located in the inner core 
4 VP4 (following cleavage: 
VP5 and VP8) 
Outer capsid spike protein; cellular 
attachment and infectivity 
5 NSP1 RNA binding; nonstructural 
6 VP6 Inner capsid protein 
7 NSP3 Binds 3’ end of viral mRNAs; 
inhibits host cell translation by 
competing with cellular PABP for 
binding to eIF-4G; nonstructural 
8 NSP2 RNA binding; involved in viroplasm 
formation; helicase activity; 
nonstructural 
9 VP7 Outer capsid protein 
10 NSP4 ER receptor for DLPs; acts as an 
enterotoxin by mobilizing [Ca2+]i 
and causing Cl- secretion; regulates 
viral transcription; recruits VP6 to 
viroplasms; nonstructural  
NSP5 RNA binding; involved in viroplasm 
formation; nonstructural 
11 
NSP6 Interacts with NSP5, in viroplasms; 
nonstructural 
 
 
Rotavirus Replication 
Rotavirus primarily infects mature villus enterocytes of the small intestine (7). 
Cellular entry of the RV virion requires cleavage of the VP4 spike protein, into VP5 and 
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VP8, which remain associated with the virion (15).  The VP8 cleavage fragment of VP4 
in some rotavirus strains has been shown to bind N-acetylneuraminic acid (sialic acid) on 
the cell surface, while the VP5 fragment is involved in the permeabilization of the 
cellular membrane (14, 16).  In addition to sialic acid, several integrin molecules (21, 
x2, v3 and 41), as well as the heat shock cognate protein hsc70, have been 
implicated in binding and entry of RV virions (16).  Furthermore, entry appears to require 
lipid rafts, as cholesterol sequestration from the plasma membrane prevents RV 
infectivity (16, 17).  
Following entry, the outer capsid, containing the VP4 and VP7 viral proteins, is 
lost from the virion, due to the low [Ca2+]i environment of the cytosol, producing a 
transcriptionally active double-layered particle (DLP) (18).  Transcription of viral 
mRNAs occurs within the DLP.  Viral mRNA transcripts are synthesized by VP1, the 
viral RNA-dependent RNA polymerase, and capped at the 5’ end by VP3, the viral 
methyltransferase and guanylyltransferase (19).  Unlike eukaryotic mRNA, however, the 
mRNA transcripts do not contain a poly(A) tail.  Once synthesized, the transcripts are 
extruded through the vertices of the DLP for translation within the cytoplasm.  
Translation of viral mRNAs involves the viral NSP3 protein, which functions similar to 
the cellular poly(A) binding protein (PABP) (20).  NSP3 binds to the 3’-end of the viral 
mRNA transcripts to allow interaction with the eIF4G protein of the cellular translational 
complex.  This interaction enables circularization of the viral mRNA, thus promoting 
translation of viral proteins.   
 Replication of the viral genome occurs within electron dense areas known as 
viroplasms.  Several studies have demonstrated the involvement of the NSP2 and NSP5 
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RV proteins in not only viroplasm formation, but genome replication and packaging as 
well (21, 22, 23, 24, 25, 26, 27).  Since NSP2 has RNA-binding and NTPase (nucleotide 
triphosphatase) activities, it is believed to function as a molecular motor that uses energy 
from NTP hydrolysis to assist in packaging the RV genome (28).  NSP5 has been shown 
to interact with VP2, as well as ssRNA and dsRNA, suggesting that the protein is 
involved in both genome replication and virion core assembly (29, 30). 
Packaging of the RV genome into newly formed DLPs occurs within the 
viroplasm.  Each virion contains one copy of each of the 11 segments of dsRNA.  Exactly 
how the 11 segments are packaged such that each newly assembled virion contains only 
one copy of each segment is still unknown.  Following formation, the DLPs bud into the 
lumen of the ER through an interaction with the viral NSP4 protein, which is located 
within the ER membrane and acts as a receptor for the subviral particles.  It is within the 
lumen of the ER that the DLPs acquire the outer capsid protein, VP7, as well as a 
transient envelope.  Prior to release from the host cell, the spike protein, VP4, is added to 
the virion, thus forming a mature TLP.  While is was previously thought that VP4 was 
added within the lumen of the ER, some studies have suggested that VP4 may be added 
to the TLP at the plasma membrane (31, 32).  Once fully assembled, the infectious TLPs 
are released from the host cell.  Traditionally thought to be released by cell lysis, recent 
research indicates RV viral particles are also released via a nonlytic vesicular transport 
pathway which bypasses the Golgi (33, 34, 35).   
NSP4 
The multifunctional viral protein NSP4 has been shown to be involved in a 
number of events in the RV life cycle including morphogenesis, pathogenesis and 
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intracellular signaling processes (4, 12).  NSP4 was identified as the first viral 
enterotoxin when it was discovered that intraperitoneal delivery of the full-length protein 
or a short peptide (aa114-135) of the protein exhibited toxin-like activity in mice (3).   
The full-length protein is 175 residues and has an approximate molecular weight of 28kD 
(Figure 2) (36).  Three hydrophobic domains (H1, H2 and H3) and two N-linked high 
mannose glycosylation sites (aa8 and aa18) are located near the N-terminus.   A single 
transmembrane domain (aa24-44), which overlaps the second hydrophobic domain (H2), 
serves to insert the viral protein into the lipid bilayer of the endoplasmic reticulum (ER) 
(37).  This insertion into the ER membrane anchors NSP4 such that a short N-terminus 
(aa1-24) remains within the lumen of the ER while a long C-terminus (aa45-175) extends 
into the cytoplasm.  The extended cytoplasmic tail of NSP4 contains an amphipathic -
helix, coiled coil domain (aa95-137) (38, 39), VP4 and VP6 binding domains (aa112-148 
and aa161-175, respectively) (40, 41, 42), an enterotoxic domain (aa114-135) (3), a 
tubulin binding domain (aa120-175) (43), an integrin receptor binding domain (aa114-
130) and an interspecies variable domain (aa135-142) (44).   
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Figure 2: Linear Schematic of Structural and Functional Domains of Rotavirus NSP4.  NSP4 is 175 
amino acids long and contains three N-terminal hydrophobic domains (H1, H2 and H3), the second of 
which overlaps the transmembrane domain (TM).  The N-terminus also contains two glycosylation sites 
(CHO).  The C-terminus contains an amphipathic -helix, coiled-coil, oligomerization domain, a VP4 
binding domain, a caveolin-1 (cav-1) binding domain, an enterotoxic peptide domain, an integrin binding 
domain, a variable domain, a tubulin binding domain and a VP6 binding domain.  Numbers correspond to 
amino acid positions.  (45). 
 
 
 Structure of NSP4 
 Crystallographic analysis of NSP4 has proven to be a difficult task hence 
structural data on the full-length protein is currently lacking.  However, a few studies on 
a segment of the C-terminus have provided structural details on the biologically relevant 
portion of the protein.  Cross-linking experiments suggest that the C-terminus forms 
homotetrameric structures in solution (38).  Circular dichroism (CD) spectroscopy 
confirmed this finding, while revealing the presence of an extended -helical secondary 
structure and predicting that oligomerization occurred via a coiled-coil motif.  This 
prediction was verified four years later when the crystal structure of aa95-137 was 
determined (39).  Crystallographic analysis revealed aa95-137 oligomerizes into a 
homotetrameric coiled-coil with a parallel packing arrangement.  At the core of the 
tetrameric structure is a cation binding site.  Modeling analysis based on the 
crystallographic data predicted that residues E120 and Q123 coordinate the binding of a 
Ca2+ ion which presumably stabilizes the homotetramer.  An additional crystallographic 
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study on aa95-146 found slight variations in organization of the homotetrameric structure 
of separate NSP4 genotypes and suggested that these structural differences may account 
for differences in virulence properties between NSP4 genotypes (46). 
 Role of NSP4 in Morphogenesis 
 As an ER-localized glycoprotein, NSP4 functions as a receptor for DLPs by 
binding to VP6 to facilitate the translocation of the DLPs across the ER membrane (41, 
42).  The mechanism for ER retention currently remains unknown, as NSP4 does not 
contain a traditional ER retention signal.  However, one study suggests that aa85-123 in 
the cytoplasmic tail of NSP4 are involved in ER retention, possibly as a result of 
structural motifs which help stabilize the protein’s interaction with the ER membrane ( 
47).  The acquisition of the outer coat (VP7) and spike protein (VP4) to become mature 
infectious TLPs is likely facilitated by NSP4, as NSP4 contains a VP4 binding domain 
(aa112-148) and forms a complex with both VP7 and VP4 (40, 48). 
      Role of NSP4 in Viral Replication 
Through silencing RNA (siRNA) studies, NSP4 was shown to play a role in RV 
replication (49, 50, 51, 52).  Surprisingly, when NSP4 expression was silenced in RV 
infected cells, researchers observed an increase in plus-strand RNA synthesis, an increase 
in empty virions as well as a decrease in virion assembly and the presence of immature, 
underdeveloped viroplasms.  Together, these results suggest that NSP4 is a regulator of 
viral transcription. 
Confocal microscopy studies show NSP4 colocalizing with LC3, an 
autophagosomal marker (53).  This association with autophagosomes is calcium 
dependent and is hypothesized to enhance viral replication, thus providing further 
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evidence for NSP4’s role in regulating viral replication.  This study also suggests that 
there is a distinct NSP4 pool, separate from that found in the ER that is associated with 
the autophagosomal pathway. 
      Role of NSP4 in Pathogenesis 
The profuse diarrhea that occurs in RV-infected individuals is a result of several 
factors, including malabsorption due to the destruction of intestinal enterocytes, fluid 
mobilization as a result of chloride (Cl-) secretion in crypt cells, villus ischemia and 
activation of the enteric nervous system (ENS) (7, 18, 54).  While the host’s response to 
infection may account for some of the cellular responses that lead to diarrhea, the effects 
of NSP4 expression likely result in several disruptions within the small intestine that 
cause fluid loss in the infected host.  NSP4 induced diarrhea is a result of a signaling 
cascade that alters intracellular calcium ([Ca2+]i) (7, 55, 56, 57).  When added 
exogenously, NSP4 mobilizes [Ca2+]i from ER stores through a phospholipase C-inositol 
1,4,5-triphosphate (PLC-IP3) pathway (55).  This disruption in [Ca2+]i causes 
malabsorption in villus enterocytes of the intestine (7).  When added to polarized 
epithelial cells, NSP4 has been shown to disrupt tight junctions thus affecting paracellular 
permeability and further contributing to malabsorption (58).  Rotavirus induced diarrhea 
is also a result of chloride (Cl-) secretion from intestinal crypt cells (3, 7).  Several 
recently published studies show the release of NSP4 from RV infected cells and 
hypothesize that the enterotoxin exogenously acts on neighboring uninfected cells, 
disrupting [Ca2+]i  and promoting Cl- secretion (59, 60, 61).  Similar to exogenous 
addition, endogenous expression of NSP4 also results in disruption of [Ca2+]i, however, 
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the mechanism by which this occurs is through a PLC-independent signaling pathway 
(57, 62).   
Yeast two-hybrid, coimmunoprecipitation and colocalization assays identified the 
extracellular matrix proteins laminin-3 and fibronectin as NSP4 binding partners (59).  
NSP4 was found to be localized at the basement membrane (BM) of RV infected cells, 
suggesting a basolateral release mechanism for the enterotoxin.  Release from the BM of 
infected enterocytes was proposed as a means by which NSP4 can travel to the crypt 
region of the intestinal villus and induce Cl- secretion, thus contributing to the secretory 
component of diarrhea.   
A recent study found that the integrins 11 and 21 act as cellular receptors for 
NSP4 (60).  Two distinct domains of NSP4 (aa114-130 and aa131-140) were reported to 
be involved in integrin I binding and signaling.  Amino acids 114-130 of NSP4 were 
shown to bind to the metal ion-dependent adhesion site (MIDAS) motif on the 1 and 2 
I domain, while aa131-140 appeared to initiate integrin signaling through interaction with 
another domain of 21.  Binding to the MIDAS motif is possibly mediated by residue 
E120, which, along with residue Q123, has been revealed by crystallographic analysis to 
coordinate with a divalent cation (probably Ca2+, Mg2+ or Mn2+) (39, 60).  Since integrins 
are localized to the basolateral surface of intestinal enterocytes (63), this finding further 
supports the hypothesis that NSP4 initiates signaling processes in uninfected cells, 
following basolateral release from infected cells, which contributes to diarrhea in an RV 
infected host.   
NSP4-induced changes in [Ca2+]i also result in actin remodeling, particularly at 
the basolateral surface of RV infected cells (64).  These changes appear to be mediated 
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by endogenously expressed NSP4.  Upon mobilization of intracellular Ca2+, actin 
polymerization increases through alteration of the activity of cofilin, an actin dynamics-
regulating protein.  Previous research demonstrates VP4-induced actin remodeling occurs 
along the apical membrane of VP4-transfected cells which result in destabilization of the 
apical membrane (65).  Based on these data, it has been hypothesized that remodeling of 
the cellular cytoskeleton in RV infected cells contributes to RV pathogenesis by directing 
newly formed virions away from the actin stabilized basolateral membrane and towards 
the actin destabilized apical membrane for release into the intestinal lumen. 
      Locations of NSP4 
Numerous studies provide evidence for multiple pools of NSP4 within RV 
infected cells (43, 53, 66, 67).  The first pool of NSP4 is localized within the ER 
membrane where it serves as a receptor for DLPs that are budding into the lumen of the 
ER for maturation into TLPs (41, 42).  The second pool is found in association with 
microtubules, radiating from the ERGIC compartment (43).  The third pool is associated 
with autophagosomes and viroplasms and is believed to help regulate viral replication 
(53).  The fourth pool of NSP4 is found in caveolae localized to the plasma membrane 
(PM) (67). 
 Several studies in our laboratory have demonstrated that full-length NSP4 
colocalizes with caveolin-1, a structural protein of caveolae, and can be found in caveolae 
isolated from the plasma membrane (PM) of RV infected cells (45, 67).  Additional 
research revealed that not only is the C-terminus of NSP4 exposed on the exofacial leaflet 
of both RV-infected and NSP4-transfected cells, but the full-length, fully-glycosylated 
protein is released from infected cells prior to the release of virus (61).  This finding 
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correlates with a study in which a cleavage fragment of NSP4 (aa112-175) was isolated 
from the media of cultured mammalian cells infected with RV (68).        
Caveolae and Caveolin-1 
 Caveolae, traditionally defined as flask-shaped invaginations in the cellular PM, 
are a subset of lipid rafts that can assume a variety of shapes (69, 70, 71).  They can either 
be open at the cell surface or can close off to form cytoplasmic caveolae vesicles. These 
membrane microdomains are rich in not only the protein caveolin-1, but also in 
glycosphingolipids, sphingomyelin, cholesterol and PTRF-Cavin (72, 73, 74).  Caveolins 
and cavin are predicted to act as a coat protein to help stabilize the membrane structure of 
caveolae (73).     
 The main protein constituent of caveolae is caveolin-1 (cav-1).  Caveolin-1 is a 
21kD protein that forms a hairpin-like structure within membranes such that both the N- 
and C-termini are found in the cytoplasm (Figure 3).  The N-terminal domain (aa1-101) 
contains an oligomerization domain (OD, aa61-101) such that 14-16 cav-1 molecules 
interact to form high molecular mass oligomers (75, 76).  Contained within the OD is a 
caveolin scaffolding domain (CSD, aa82-101) which serves as an interaction domain for 
other proteins as well as cholesterol (77).  The transmembrane domain (TMD, aa102-
134) forms a hairpin-like loop within membranes and is bordered on either side by the N-
terminal membrane attachment domain (N-MAD, aa82-101) and the C-terminal 
membrane attachment domain (C-MAD, aa135-150), both of which serve to anchor the 
protein to the membrane (70).  The C-terminal domain (aa135-178) contains three 
palmitoylated cysteine residues (aa133, 143, 156) which also anchor the C-terminus to 
the membrane (78).  Palmitoylation of these residues appears to be important for 
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regulating the interaction of cav-1 with signaling molecules and is also required for the 
binding and transport of cholesterol (79, 80).  
 
                           
Figure 3: Caveolin-1 Schematic Depicting Membrane Topology and Functional Domains.  Caveolin-1 
is arranged within the membrane such that the N- and C-termini are oriented towards the cytoplasm. OD-
oligomerization domain; CSD-caveolin scaffolding domain; N-MAD and C-MAD-N- and C-terminal 
membrane attachment domains; TMD-transmembrane domain; TD-terminal domain; C133, C143, C156-
palmitoylation sites.  Numbers correspond to amino acid positions (70). 
 
 
 
Formation of caveolae commences following the synthesis of cav-1 in the ER and 
its subsequent entry into the secretory pathway (81, 82, 83, 84).  During transport to the 
PM, cav-1 monomers begin to assemble into high molecular weight oligomers, which 
associate with cholesterol, to form mature caveolar vesicles (81, 82).  Oligomerization of 
cav-1 monomers occurs in a side by side fashion, such that the monomers interact N-
terminus to N-terminus and C-terminus to C-terminus (75, 85).  One study did suggest, 
however, that the C-terminal domains can also bind the N-termini of adjacent monomers, 
within the oligomerization domain, to provide further stabilization of the oligomers (85). 
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 Caveolin-1 Structure 
 Studies have yet to elucidate the complete structure of cav-1.  To date, the only 
insights into cav-1 structure consist of limited secondary structural data on the N-terminal 
portion of the protein (75).  This study utilized CD to determine the secondary structure 
of a peptide that contained a majority of the N-terminus (aa1-101) (75).  While the 
peptide was determined to be ~20% -helix, additional structural analysis of deletion 
peptides determined that aa79-96 constituted the -helical portion of the peptide, while 
the first 78 residues appear to lack appreciable secondary structure.  The authors predict 
that these initial residues of the cav-1 protein wrap around the -helical portion and assist 
in the stabilization of oligomers (75). 
 A second study utilized a bioinformatics approach to gain structural insights into 
cav-1 (76).  Using protein structural prediction programs, their study confirmed the above 
mentioned CD results in that they found that the N-terminus of cav-1 is relatively 
unstructured.  In addition to verifying that aa81-101 have significant secondary structure, 
Spisni et al. were able to further determine that aa95-101 are involved in -helix 
formation, while aa84-94 form two -strands arranged in an anti-parallel fashion.  
Consensus secondary structure prediction analysis revealed that aa134-167 of the C-
terminus of cav-1 form an -helix (76).  The reminder of the C-terminus (aa168-178) is 
predicted to be unstructured. 
Caveolin-1 and Cholesterol 
 Contained within the CSD of cav-1 is a cholesterol recognition/association 
consensus (CRAC) sequence: -L/V-(X)1-5-Y-(X)1-5-R/K-, where (X)1-5 represents one to 
five residues of any amino acid (76, 86).  This CRAC sequence serves as a cholesterol 
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binding motif and is located at cav-1 aa94-101.  Experiments have shown that cav-1 and 
cholesterol bind at a 1:1 ratio and the interaction between the two molecules is critical in 
the formation of caveolae and the transport of cholesterol throughout the cell (80).  
Caveolae formation is dependent on cholesterol.  Experiments in which cholesterol was 
depleted from the cell using various drugs show a decrease or disappearance of caveolae 
(87, 88).    
Caveolae, Caveolin-1 and Signaling 
 Caveolae also participate in a number of cellular signaling events (89, 90).  
Numerous signaling molecules such as receptor tyrosine kinases, G-protein coupled 
receptors and eNOS localize to caveolae where they bind cav-1 and either activate or 
inhibit signaling processes (70, 84).  Also localized in caveolae are the plasma membrane 
calcium pump (91), and an inositol 1,4,5-trisphosphate receptor-like protein (92).  
Signaling is regulated through the interaction of these signaling proteins with the 
scaffolding domain of cav-1 (aa61-101).  Because of the involvement of caveolae in 
cellular signaling and cholesterol transport, studies focusing on the pathway(s) of NSP4 
transport from the ER to the PM of RV infected cells have been directed towards 
understanding the NSP4-caveolae/caveolin-1 interaction. 
NSP4-Caveolin-1 Interaction 
Extensive research in our laboratory has demonstrated that NSP4 interacts with 
cav-1 and caveolae.  Circular dichroism (CD) data reveals that full-length NSP4 and the 
enterotoxic peptide, NSP4114-135, preferentially interact with a model membrane lipid 
domain that is highly curved, rich in anionic phospholipids and highly enriched in 
cholesterol, similar to caveolae (93, 94).  Furthermore, interaction with these caveolae-
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like model membranes induces an increase in the -helical secondary structure of NSP4 
and the enterotoxic peptide.  Confocal microscopy shows that NSP4 colocalizes with cav-
1 and caveolae in both NSP4 transfected and RV-infected cells (45, 67).  While confocal 
analysis resolves this interaction between NSP4 and cav-1 to within 200nm, fluorescence 
resonance energy transfer (FRET) analysis narrows the distance to approximately 10nm 
(67).  Yeast two-hybrid and coimmunoprecipitation assays subsequently verified this 
protein-protein interaction.  When caveolae was isolated from the PM of RV-infected 
cells, full-length, fully glycosylated NSP4 was found to be present in these microdomains 
(67).  Additional yeast two-hybrid assays, as well as peptide binding assays, revealed that 
cav-1 binds NSP4 between aa114-135, which is equivalent to the enterotoxic domain 
(aa114-135) and is located within the amphipathic -helix, coiled coil domain (aa95-137) 
(45).  Interestingly, when the assays were repeated to determine the NSP4 binding 
domain on cav-1, NSP4 was found to bind both the N- and C- termini (aa2-22 and 161-
178, respectively) (45, 95).    
To further characterize the interaction between NSP4 and cav-1, two NSP4 
mutants (NSP4HydroMut and NSP4Ala6) were generated using site-directed mutagenesis.  
Figure 4 shows a linear schematic of the full-length NSP4 mutant proteins.  The 
NSP4HydroMut mutant contains three mutations (aa113, aa124 and aa131) within the 
hydrophobic face of the amphipathic -helix, while the NSP4Ala6 mutant contains six 
mutations (aa114, aa115, aa119, aa125, aa132, aa133) within the charged face of the 
amphipathic -helix (Figure 5).  The hydrophobic residues on the hydrophobic face were 
mutated to charged residues, while the residues on the charged face were mutated to 
neutral alanine residues.   
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Figure 4:  Linear Schematics of Mutant NSP4 (NSP4Ala and NSP4HydroMut) Proteins.  Asterisks denote 
mutations present in each protein.  To the right of each schematic are the amino acid mutations (45).  
 
 
Yeast-two hybrid analyses indicated that the mutations in the hydrophobic face of 
the amphipathic -helix inhibit the viral protein from interacting with and binding to cav-
1 (45).  The alanine mutations in the charged face of the amphipathic -helix, however, 
do not appear to affect the binding of NSP4 to cav-1.  Therefore, the binding between 
NSP4 and cav-1 was revealed to occur through a hydrophobic interaction.  Further 
mutational analyses delineated the cav-1 binding site on NSP4 to a clustering of three 
hydrophobic residues within the amphipathic -helix (96).   
To summarize, cav-1 binds NSP4 within the hydrophobic face of the amphipathic 
-helix, enterotoxic peptide domain (aa114-135).  NSP4 in turn binds both the N- and C-
termini of cav-1.  This interaction between NSP4 and cav-1 and caveolae is hypothesized 
to facilitate transport of NSP4 from the ER to the PM of RV infected cells. What 
currently remains unknown, however, is what role, if any, secondary structure plays in 
the NSP4-cav-1 interaction.   
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Figure 5: Helical Wheel of the Amphipathic -helix Domain of NSP4 (aa95-134).  The amphipathic -
helix domain of NSP4 contains a hydrophobic face and a charged face.  The charged face is further 
separated into an acidic face and a basic faces (96). 
 
 
 
Role of Amphipathic Helices in the NSP4-Caveolin-1 Interaction 
  
 Amphipathic -helixes are secondary structural motifs found in proteins and 
peptides and consist of an -helical domain that contains both a polar face and a 
nonpolar/hydrophobic face (97).  Amphipathic -helixes generally associate with lipids 
and are involved in membrane fusion or lysis, and signal transduction processes.  They 
also play a role in DNA replication as they are found in transcription factors that directly 
bind to DNA (98). 
 There are seven classes of amphipathic -helixes (A, H, L, G, K, C and M), which 
are grouped based on their physical-chemical (i.e. hydrophobic moment, hydrophobicity 
and charged residue density) and structural properties (97).  Class A, H, L and M 
amphipathic -helixes associate with lipids, while classes G, K and C are involved in 
protein-protein interactions (97).  Examples of each -helix class are as follows: class A 
are apolipoproteins, class H are polypeptide hormones, class L are lytic polypeptides, 
class G are globular -helical proteins, class K are calmodulin-binding domains of 
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calmodulin-regulated protein kinases, class C are coiled-coil proteins and class M are 
complex transmembrane proteins (97). 
 The RV NSP4 amphipathic -helix appears to be most similar to the class A 
helixes.  These helixes are characterized by their ability to associate with lipids, with 
apolipoproteins being the most notable -helixes in this group.  Structurally, class A 
helixes display a clustering of positively charged residues at the polar-nonpolar interface 
and a clustering of negatively charged residues at the center of the polar face.  It is 
through these charged residues that the helix associates with lipids (99, 100, 101, 102, 
103).  Due to the tendency of amphipathic -helices to associate with both proteins and 
lipids, it is reasonable to assume that the amphipathic -helix of NSP4 not only binds 
cav-1, but associates with lipids as well. 
Specific Aims of Dissertation Research 
• Aim 1: Determine the binding affinities of wild-type (wt-) NSP4112-140 with cav-1 
synthetic peptides corresponding to the N-and C-termini of cav-1. 
•  Aim 2: Ascertain the extent of secondary structural changes in the wt- and mutant 
(mt-) NSP4112-140 peptides when in the absence or presence of cav-1 specific 
peptides or model membranes (small unilamellar vesicles, i.e. SUV). 
•  Aim 3: Resolve the binding affinity of cholesterol with wt- and mt-NSP4112-140 
peptides. 
• Aim 4. Examine the biological significance of the specific mutations within the 
amphipathic -helix of NSP4. 
 The studies involved herein focused on evaluating the secondary structural and 
functional effects of the mutated residues in the enterotoxic peptide/cav-1 binding 
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domain of NSP4.  Structural and functional studies utilized NSP4 wt- and mt- peptides. 
These peptides encompassed the majority of the amphipathic -helix (AAH, aa112-140).  
Rather than using the original NSP4Ala6 mutant, which contained six mutations within the 
charged face, we separated the mutations into those that were in the acidic face from 
those that were in the basic face and synthesized the corresponding peptides.  Three mt-
NSP4 peptides were synthesized which contained the following mutations: (1) NSP4112-
140Hydro-hydrophobic residues mutated to charged residues (I113R, V124K, Y131D); (2) 
NSP4AlaAcidic112-140-acidic amino acids were mutated to alanines (D114A, E125A, 
D132A); and (3) NSP4AlaBasic112-140-basic wherein the basic residues were mutated to 
alanines (K115A, R119A, K133A).  The cav-1 synthetic peptides utilized to the N- or C-
termini of the protein (aa2-20, aa19-40 and aa161-178, respectively).   
 Many caveolae-localized signaling molecules interact with cav-1 through the 
caveolin scaffolding domain (aa82-101) (104, 105, 106, 107).  Previous NSP4-cav-1 
binding studies, however, revealed that unlike most proteins, NSP4 does not bind cav-1 
within the scaffolding domain (95).  Consequently, a synthetic peptide corresponding to a 
portion of the scaffolding domain (aa68-80) of cav-1 was used as a negative control.  
Conversely, cav-1 does not bind the extreme C-terminus of NSP4 (aa150-175) (45).  
Therefore a synthetic peptide of this region of NSP4 was also used as a peptide-binding 
control. 
Rational for Utilizing Peptides to Analyze the NSP4-Caveolin-1 Interaction 
 The study of protein-protein interactions is important for understanding various 
cellular processes and has been particularly useful in the area of drug design.  The use of 
peptides, which contain the relevant binding domains of two interacting proteins, has 
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aided in the investigation of these interactions.  Several recently published articles 
demonstrate the use of peptides for investigating peptide-peptide structural interactions 
that reflect what is seen in the full length proteins (108, 109, 110, 111).  One study used 
synthetic peptides corresponding to separate regions of the HIV-1LAI gp41 protein to 
investigate peptide-peptide interactions utilizing both circular dichroism and 
sedimentation equilibrium analyses techniques (108).  The findings of this study provide 
insight into the structural changes that occur in gp41 during membrane fusion and predict 
a mechanism for HIV-1 fusion with cellular membranes. In another peptide-peptide 
interaction study, a peptide corresponding to the E2 envelope protein of the hepatitis G 
virus (GBV-C/HGV) was found to modify the conformational structure of the fusion 
peptide (FP) of the HIV-1 gp41 protein (111).  The authors speculated that the use of this 
GBV-C/HGV peptide in inducing a conformational change in HIV-1 gp41 may 
potentially be used as an antiviral therapeutic agent as the structural change prevents 
cellular fusion of HIV-1 and thus prevents entry of the virus.  These studies highlight the 
use of peptides for studying structural changes following interactions with other peptides.  
Furthermore, they demonstrate how the study of peptide-peptide interactions provides a 
means by which protein-protein interactions can be dissected and the mechanisms of 
these interactions further defined.   
Techniques Employed to Accomplish the Specific Aims 
A solution fluorescence binding assay was utilized to examine the binding affinity 
of the wtNSP4112-140 peptide with N-and C-terminal cav-1 peptides.  Secondary structural 
changes in the wt- and mt-NSP4-specific peptides, both in the absence and presence of 
cav-1 peptides and model membranes (small unilamellar vesicles, i.e. SUV), were 
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evaluated by circular dichroism (CD) analyses.  Since NSP4 has a potential CRAC 
sequence ((L)LKRIYDK) located between aa126/127-133, each of the NSP4-specific wt- 
and mt-peptides were also evaluated for cholesterol binding.   The biological importance 
of these mutations and their effect on secondary structure in disease induction was 
evaluated by diarrhea studies in mouse pups.   
 Peptide Synthesis, Purification, and Characterization 
 Many peptide chemists employ the Fluorenylmethoxycarbonyl solid-phase 
peptide synthesis (Fmoc SPPS) chemistry (112) technique for peptide synthesis.  This 
technique uses the base-labile N-Fmoc group for the protection of the -amino group of 
coupling amino acids, while acid-labile groups protect the amino acid side-chains.  
Removal of these protecting groups occurs by different chemical mechanisms and 
therefore can be performed under relatively mild chemical conditions.   
Synthesis begins when the first amino acid is coupled to an insoluble resin 
support via its carboxyl group (112).  Side-chain groups of the amino acid are protected 
with protecting groups that are not affected by the chemical conditions utilized during 
assembly of the peptide chain.  The Fmoc-protecting group that shields the -amino 
group of the first coupled amino acid is removed under basic conditions.  The carboxy 
group of the second amino acid is activated for amide bond formation and the amino acid 
is then coupled to the amino group of the first amino acid.  Excess reagents are removed 
by washing, the N-terminal Fmoc-protecting group of the second amino acid is removed 
and the third amino acid is then added.  Following synthesis of the complete sequence, 
the peptide is cleaved from the resin support and the side-chain protecting groups are 
removed.  Following ether extraction of the synthesized peptide, organic contaminants 
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and incomplete peptide fragments are removed by gel filtration and high-performance 
liquid chromatography (HPLC) purification.  Peptides are then characterized by mass 
spectroscopy to assure that they are the correct mass and contain the proper sequence. 
 Circular Dichroism 
Circular dichroism (CD) is a spectroscopic technique that is used to study peptide 
and protein conformations (113, 114, 115, 116, 117).  The technique measures the 
difference in absorbance between left and right circularly polarized light of chiral 
molecules.  The CD spectrum of a peptide or protein is due to the peptide amide 
chromophore which absorbs in the far-UV (below 250nm).  Data collected generally 
consists of a combination of secondary structure, including -helix, -sheet, turns and 
random coils.  There are several programs available which can calculate the percentage of 
each secondary structure in a sample by utilizing reference sets of proteins of known 
structure (118, 119).       
CD has many advantages as a spectroscopic technique for peptide and protein 
structural analysis.  It is relatively fast and easy, requires low sample concentrations and 
allows researchers to study the structure of peptides or proteins in solution.  CD is 
particularly useful for monitoring changes in secondary structure that occur as a result of 
changes in the surrounding environment (i.e. pH, solvent or concentration) and 
interaction with other peptides/proteins/ligands.  It can also be used to detect changes in 
secondary structure due to the mutation of amino acid residues within a peptide or 
protein. 
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 Fluorescence Binding Assays 
 
 A fluorescence binding assay is a technique used to monitor the binding of two 
molecules (120, 121).  The method generally relies on the intrinsic fluorescence of a 
molecule that comes from the aromatic side-chains of tyrosine or tryptophan.  However, 
in the cases where intrinsic fluorescence is lacking, the molecule can be labeled with an 
extrinsic fluorophore.  The assay monitors the environment around the fluorophore in 
response to ligand binding.  When the fluorophore is in a hydrophilic environment and 
exposed to the surrounding solvent, its fluorescence is quenched.  If upon ligand binding 
the fluorophore is placed in a hydrophobic environment where it is shielded from the 
solvent, its fluorescence will be dequenched.   
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CHAPTER II 
PEPTIDE-PEPTIDE STUDIES OF THE NSP4-CAVEOLIN-1 INTERACTION 
 
Overview 
 Recent yeast two-hybrid and peptide binding data from our laboratory show that 
the rotavirus (RV) enterotoxic protein NSP4 binds both the N- and C-termini of caveolin-
1.  Here, we utilize synthetic peptides to further investigate this interaction between 
NSP4 and caveolin-1.  Peptides were synthesized that corresponded to the amphipathic -
helix and caveolin-1 binding domain of NSP4 (aa112-140) as well as to the N- (aa2-20 
and 19-40) and C- (161-178) termini of caveolin-1.  Direct fluorescence binding assays 
were used to determine the binding affinities between the NSP4 and caveolin-1 peptides.  
Secondary structural changes following peptide-peptide interactions were discerned by 
circular dichroism analysis.  Results indicated that NSP4112-140 binds to the N-terminus of 
caveolin-1 (aa19-40) with a significantly higher affinity than the C-terminus, indicating 
preferential binding to caveolin-1 residues 19-40.  These data further delineated the NSP4 
binding domain on caveolin-1 to aa19-40.  Secondary structural analysis of NSP4-
caveolin-1 peptide-peptide interactions revealed that conformational changes only occur 
upon interaction of NSP4 with the C-terminus of caveolin-1.  These findings are 
hypothesized to have implications in NSP4 function(s) at the plasma membrane.   
Introduction 
 As the leading cause of gastroenteritis in young children under the age of five, 
rotavirus (RV) infections are responsible for approximately 440,000 deaths worldwide 
annually (1).  During infection, the RV nonstructural protein 4 (NSP4) functions as a 
viral enterotoxin by activating a signal transduction pathway which increases intracellular 
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calcium [Ca2+]i levels through the release of ER calcium stores (3, 57).  This increase in 
intracellular Ca2+ induces secretory chloride currents which result in diarrhea due to 
intestinal fluid imbalance (3).   
 Traditionally defined as an ER glycoprotein, NSP4 contains a single 
transmembrane domain which serves to anchor the protein into the ER membrane, such 
that a short N-terminus (aa1-24) remains within the lumen of the ER while a longer C-
terminus (aa45-175) extends into the cytoplasm (37).  Interactions with numerous viral 
and cellular proteins occur within the extended C-terminal tail of NSP4 (40, 41, 42, 43, 
59, 60).  Also contained within the C-terminal cytoplasmic tail is an amphipathic -helix 
(AAH), coiled-coil domain (aa95-137) (38, 39).  Cross-linking and crystallographic 
experiments reveal that this region of NSP4 oligomerizes into dimers and tetramers and 
contains a cation-binding site (38, 39, 48).  Residing within the amphipathic -helix, 
coiled-coil domain is the enterotoxic peptide region (aa114-135) as well as the caveolin-1 
(cav-1) binding domain (3, 45).   
There is compelling evidence that NSP4 and the enterotoxic peptide (NSP4114-135) 
interact with cav-1.  In vivo laser scanning confocal microscopy (LSCM) colocalizations, 
fluorescent energy transfer (FRET) analyses, and co-immunoprecipitation data from our 
laboratory show that NSP4 binds cav-1, the main constituent protein of caveolae (45, 96).  
Yeast two-hybrid and in vitro binding assays confirm an interaction between NSP4 and 
cav-1 and map the cav-1 binding domain to NSP4114-135 (45).  Using deletion and site-
directed mutagenesis, the binding site was delineated to three hydrophobic residues in the 
enterotoxic region indicating NSP4 and cav-1 associate via a hydrophobic interaction 
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(96).  Additional studies reveal that the cav-1 binding site for NSP4 maps to both the N- 
and C-termini of cav-1, residues 2-31 and 161-178, respectively (95).   
Cav-1 is an intracellular 21kD protein bound by the inner leaflet of the plasma 
membrane (PM).  Cav-1 interaction with membranes is distinct in that a hairpin-like 
structure is formed in the membrane resulting in both the N- and C-termini oriented 
towards the cytoplasm (70, 122).  Numerous signaling molecules, such as those involved 
in calcium signaling, are localized to caveolae and their function appears to be dependent 
on interaction with cav-1 (89, 123, 124).  Cav-1 also binds cholesterol (79), which has 
been shown to be vital to caveolae biogenesis and the transport of cholesterol throughout 
the cell (83, 87, 89).   
Full-length NSP4 and the NSP4114-135 peptide interact with caveolae-like model 
membranes, i.e., those that have a high radius of curvature and are rich in anionic 
phospholipids and cholesterol (93, 94).  Upon interaction with model membranes, both 
the protein and the peptide undergo a change in secondary structure characterized by an 
increase in -helix formation.  Additional secondary structural studies of other NSP4 
peptides that encompass the enterotoxic peptide and cav-1 binding domain confirm that 
this region is important for membrane interactions.  Transport of NSP4 to the plasma 
membrane (PM) is believed to occur through this interaction with cav-1 and caveolae.  
When caveolae microdomains are isolated from enriched PM fractions of RV-infected 
MDCK cells, the full-length, fully-glycosylated, endoglycosidase-H sensitive NSP4 is 
present in the isolated caveolae fractions verifying transport of NSP4 to the PM and 
caveolae (67).  Additional studies reveal the exposure of the NSP4 C-terminus and 
enterotoxic region, but not the N-terminus, on the outer PM leaflet and subsequent 
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release into culture media at a time when the membrane is intact as verified by a lack of 
exposure of cav-1 and other intracellular markers (61, 68). 
In this report, we have extended these studies using synthetic peptides to address 
the following questions: (i) Does NSP4 interact with both termini of cav-1 with equal 
affinity? (ii) Can the binding domain be further delineated using synthetic peptides and 
determining binding constants (Kd)? (iii) Do the two termini of cav-1 interact with one 
another? (iv) Is there a structural change when NSP4 and cav-1 peptides interact?  To 
answer these questions we employed peptide-peptide fluorescence binding assays and 
circular dichroism techniques.  Direct fluorescence binding assays were utilized to 
determine the binding affinity (Kd) of the NSP4-cav-1 peptide-peptide interaction.  
Circular dichroism (CD) was used to investigate secondary structural changes upon 
interaction of the peptides in the absence or presence of membranes.   
Materials and Methods 
Materials 
 Phospholipids DOPS (1,2-dioleoyl-sn-glycero-3-[phosphor-L-serine]) and POPC 
(1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) were purchased from Avanti Polar 
Lipids (Alabaster, AL).  Cholesterol, Sephadex G-25 and trifluoroethanol (TFE) were 
purchased from Sigma (St. Louis, MO).  Trifluoroacetic acid (TFA), 1-hydroxy-
benzotriazole (HOBt) and O-Benzotriazole-N,N,N’,N’-tetramethyluronium-hexafluoro-
phosphate (HBTU) were purchased from American Bioanalytical (Natick, MA).  N,N-
diisopropylethylamine (DIPEA) and N,N’-diisopropylcarbodiimide (DIPCIDI) were 
purchased from CreoSalus (Louisville, KY).  Thioanisole, ethanedithiol and anisole were 
purchased from EMD chemicals (Gibbstown, NJ). 
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Synthesis and Purification of NSP4 and Caveolin-1 Peptides 
All peptides were synthesized by fluorenylmethoxycarbonyl (Fmoc) solid-phase 
chemistry with either 1-hydroxy-benzotriazole (HOBt), O-Benzotriazole-N,N,N’,N’-
tetramethyluronium-hexafluoro-phosphate (HBTU) and N,N-diisopropylethylamine 
(DIPEA), or HOBt and N,N’-diisopropylcarbodiimide (DIPCIDI) activation using the 
Model 90 Peptide Synthesizer (Advanced Chemtech; Louisville, KY).  Following 
synthesis, the peptides were cleaved from the solid resin support and all side-chain 
protecting groups removed by the addition of Reagent R (90% trifluoroacetic acid (TFA), 
5% thioanisole, 3% ethanedithiol and 2% anisole).  The peptide/Reagent R cleavage 
mixture was incubated at RT for a maximum of 2 hours with gentle mixing.  
To separate the peptides from the solid support, the mixture was filtered through a 
sintered glass filter into a 50mL conical tube containing cold diethyl ether in a dry 
ice/ethanol bath.  Following 2-3 rinses of the filter with TFA, the ether solution 
containing the precipitated peptide was centrifuged at ~300g for 4 minutes.  The 
supernatant was removed and additional cold diethyl ether was added to the peptide 
pellet.  The mixture was allowed to cool in the dry ice/ethanol bath for several minutes 
before repelleting.  The supernatant was removed, more ether added and this step was 
repeated an additional two times.  The crude peptide precipitate was dried under N2, 
resolubilized in 10% acetic acid and lyophilized.   
The lyophilized crude peptide was resuspended in 5-10% acetic acid and purified 
from organic contaminants and incomplete peptide fragments by gravimetric gel filtration 
chromatography (Sephadex G25 medium).  The eluted peptide was lyophilized and 
further purified by reverse-phase HPLC using a reverse phase C4 Delta Pak column 
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(Waters Chromatography Division, Milford, MA) or a reverse phase C18 column 
(Beckman-Coulter, Fullerton, CA), depending on the hydrophobicity of the peptide.  
Eluted peaks were lyophilized and characterized by matrix-assisted laser 
desorption/ionization (MALDI) mass spectrometry (Laboratory for Biological Mass 
Spectrometry, Department of Chemistry, Texas A&M University, College Station, TX).   
Circular Dichroism (CD) and Secondary Structure Estimation 
The secondary structures of the NSP4 and caveolin-1 specific peptides were 
determined by circular dichroism following a previously published protocol (93, 94).  
Briefly, each peptide (15-35µM) was suspended in 10mM potassium phosphate buffer, 
pH 7.4, or 50% trifluoroethanol (TFE), to promote a hydrophobic environment and 
correct folding of the peptide, in the presence or absence of lipid vesicles (1mM).  
Samples containing buffer or lipid vesicles without peptide were used for background 
correction.  Peptide concentrations were determined by amino acid analysis (Protein 
Chemistry Laboratory, Department of Biochemistry, Texas A&M University, College 
Station, TX).  CD spectra were obtained in a 1mm circular quartz cell at room 
temperature using a Model J-710 JASCO spectropolarimeter (JASCO, Easton, MD) or in 
a 1mm rectangular quartz cell in a Model 202 Aviv spectrometer (Aviv Biomedical, 
Lakewood, NJ).  The spectra for each of the peptides were recorded from 185nm to 
260nm, with a step resolution of 1nm, speed of 50nm/min, response of 1sec, bandwidth 
of 2.0nm and sensitivity of 10mdeg.  Data were averaged from 5 scans, background 
subtracted, smoothed and converted into mean residue molar ellipticity [] (deg 
cm2/dmol).   
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To determine the percent -helix for each of the NSP4 and cavolin-1 specific 
peptides, the following equation was used: 222 = (ƒh – /N)[h 222] (93, 94, 125).  In this 
equation, 222 is the mean residue molar ellipticity at 222nm, ƒh is the fraction in -helical 
form,  is the number of helices,  is a wavelength-specific constant with a value of 2.6 at 
222nm, N is the number of residues in the peptide and h 222 is the molar ellipticity for a 
helix of infinite length at 222nm (i.e. -39,500 deg cm2/dmol).     
Direct Fluorescence Binding Assays 
A fluorescence binding assay was utilized to demonstrate direct binding of the 
wtNSP4112-140 peptide with each of the cav-1 peptides (N-Cav2-20, Cav19-40, and C-Cav) 
(45, 126).   All of the cav-1 peptides (N-Cav2-20, Cav19-40, and C-Cav) were directly 
labeled with a Cy3 fluorescent dye, using the Cy3 Mono-reactive dye pack from 
Amersham Biosciences (Piscataway, NJ), according to the manufacturer’s protocol.  
To demonstrate a direct peptide-peptide interaction between the wtNSP4112-140 
peptide and each of the caveolin-1 peptides, increasing quantities of wtNSP4112-140 
peptide (10-500nM) were added to 25-100nM of the Cy3-labeled caveolin-1 peptides in 
2mL of phosphate buffered saline (pH 7.4).  Excitation of the Cy3 fluorophore was 
carried out at 550nm, and emission spectra was scanned from 560-700nm.  Fluorescence 
emission spectra were obtained at 25ºC with a PC1 photon-counting spectrofluorometer 
(ISS, Inc., Champaign, IL), with excitation and emission slit widths of 1.0.  Spectra were 
corrected for background and maximal fluorescence intensities were measured.  The 
dissociation constant (Kd) was obtained by a reciprocal plot of 1/(1-F/Fmax) and CL/F/Fmax 
according to the following equation: y = bx + yo, where F is the fluorescence intensity at 
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a given concentration of ligand, Fmax is the maximal fluorescence obtained and CL is the 
ligand concentration.  The slope of the line (b) is equal to 1/Kd. 
Preparation of Small Unilamellar Vesicles (SUV) 
SUV composed of the neutral lipid POPC, cholesterol and the anionic 
phospholipid DOPS in the molar ratio 55:35:30 were prepared following a previously 
published protocol (93).  This membrane composition was chosen as it has previously 
been shown to promote an interaction with NSP4-specific peptides as observed by an 
increase in peptide -helix formation (93, 94).  Stock solutions of the lipids dissolved in 
chloroform were mixed together in the proper ratio in an amber glass vial.  The solvents 
were removed under N2 with constant rotation so that the dried lipids formed a thin film 
on the wall of the glass vial.  The vial containing the dried lipids was further dried under 
vacuum for a minimum of 4 hrs.  The dried lipids were resuspended in 10mM MOPS 
buffer, pH 7.4 (prefiltered through a 0.45m filter; Millipore, Bedford, MA), vortexed 
and bath sonicated.  The resulting multilamellar membrane suspension was sonicated 
with a microprobe under N2 at 4ºC at 2 min. intervals, followed by 1 min. pauses to 
prevent overheating of the lipid solution.  The sonicated lipid solution was then 
centrifuged at 110,000g for 4 hrs to remove any multilamellar vesicles and titanium 
debris from the sonicator probe.  The lipid concentration of the SUV solution was 
determined by a previously described standard phosphate assay (127).  Briefly, the SUV 
solutions were mixed with 14 drops of a 10% magnesium nitrate (Mg(NO3)2) solution (in 
95% ethanol) and heated for 30 min. in a 120ºC dry bath.  Each sample was then ashed 
by heating in a flame.  Next, 600µL of 0.5N HCl was added to each sample and the 
samples were heated in boiling water for 15 min.  Each of the samples were then mixed 
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with 1400µL of a 10% ascorbic acid solution that contained 6 parts of a 0.42% 
ammonium molybdate solution in 1N sulfuric acid (H2SO4).  The samples were incubated 
for 20 min. at 45ºC before reading the absorbance at 660nm (A660).  Lipid concentrations 
of the SUV were determined by comparison to a standard curve of 0-200nmol phosphate. 
Results 
Synthesis of Peptides 
Sequences from the SA11 rotavirus simian strain of NSP4 and human caveolin-1 
were used to generate the peptides listed in Table 2.  A portion of the AAH of NSP4 that 
encompassed both the enterotoxic peptide and caveolin-1 binding domain (aa112-140) 
was chosen for synthesis and used in this study.  A C-terminal NSP4 peptide (NSP4150-
175Ala) was also synthesized for use as a negative control.   
Caveolin-1 peptides that corresponded to various segments of the N-terminus 
(aa2-20, aa19-40) and to the extreme C-terminus (aa161-178) similarly were synthesized.  
Additionally, a peptide corresponding to the central region of cav-1 (aa68-80) was 
synthesized for use as a negative control, as this region is known to not be involved in 
binding NSP4 (95). 
 
Table 2: Sequences of NSP4 and Caveolin-1 Peptides 
 
Peptide Name: Peptide Sequence (NC): 
NSP4112-140 (aa112-140) MIDKLTTREIEQVELLKRIYDKLTVQTTG 
NSP4150-175Ala QKNVRTLEEWESGKNPYEPREVTAM 
N-Cav2-20 (aa2-20) SGGKYVDSEGHLYTVPIRE 
Cav19-40 (aa19-40) REQGNIYKPNNKAMADELSEKQ 
Cav68-80 (aa68-80) FEDVIAEPEGTHS 
C-Cav161-178 (aa161-178) EAVGKIFSNVRINLQKEI 
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Direct Fluorescence Binding Assays 
 
      wtNSP4112-140 binds the N-terminus of Caveolin-1 (Cav19-40) with greater affinity 
than the C-terminus 
 Previously published data from our laboratory demonstrate that NSP4 (aa114-
135) interacts with both the N- and C-termini of caveolin-1 (95).  To further investigate 
this interaction and determine the binding affinity of the NSP4-cav-1 interaction in the 
absence of other cellular components, the wtNSP4112-140 peptide and various cav-1 
peptides (N-Cav2-20, Cav19-40 and C-Cav161-178) were utilized in a direct fluorescence 
binding assay.  Each of the cav-1 peptides was labeled with a Cy3-fluorophore and then 
titrated with the wtNSP4112-140 peptide.    
 Upon titration with increasing concentrations of wtNSP4112-140, each of the cav-1 
peptides showed an increase in fluorescence intensity at 565nm.  Plots of wtNSP4112-140 
peptide concentrations versus maximum fluorescent intensities demonstrated saturable 
binding curves for each of the cav-1 peptides (Figure 6).  Linear reciprocal plots were 
used to calculate the binding affinities (Kd) for each peptide-peptide pair (Table 3).  The 
calculated Kd values for the NSP4-cav-1 peptide-peptide interactions indicated that 
wtNSP4112-140 bound the Cav19-40 peptide with the strongest affinity (39.55 ± 10.19nM), 
while it bound the C-Cav161-178 peptide with the weakest affinity (216.64 ± 35.16).  The 
N-Cav2-20 peptide bound with intermediate affinity (84.60 ± 6.09nM).  None of the cav-1 
peptides bound to the control peptide corresponding to the C-terminus of NSP4 (NSP4150-
175Ala), which is known to not bind cav-1 (45).  These results compliment previous 
findings (95) and further delineate the NSP4 binding domain on the N-terminus of cav-1 
to aa19-40. 
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Figure 6: Direct Fluorescence Binding Assays-wtNSP4112-140 Peptide with Caveolin-1 Peptides. A-
fluorescence spectra of Cy3-C-Cav161-178 titrated with increasing concentrations of wtNSP4112-140. Spectrum 
1-100nM Cy3-C-Cav161-178 in buffer only. Spectra 2-11, 100nM Cy3-C-Cav161-178 in the presence of 10, 
100, 150, 200, 250, 300, 350, 400, 450 and 500nM of NSP4112-140, respectively.  B-fluorescence spectra of 
Cy3-Cav19-40 titrated with increasing concentrations of NSP4150-175 (negative control) C-E-plots of maximal 
fluorescence emission (measured at 565nm upon excitation at 550nm) for wtNSP4112-140 in the presence of 
25nM Cy3-N-Cav2-20 (C), 25nM Cy3-Cav19-40 (D) and 25nM Cy3-C-Cav161-178 (E). Insets, linear plots of 
the binding curve of wtNSP4112-140.   
 
 
 
 
 
 
Table 3: Binding Affinities (Kd) for wtNSP4112-140 + Caveolin-1 Peptidesa. 
 
Sample: Kd (nM): 
Cy3-N-Cav2-20 + wtNSP4112-140 84.60 ± 6.09 
Cy3-Cav19-40 + wtNSP4112-140  39.55 ± 10.19 
Cy3-C-Cav161-178 + wtNSP4112-140  216.64 ± 35.16 
 
aPeptides were synthesized as mentioned in Materials and Methods.  The Kd values were calculated as 
outlined in Materials and Methods and are presented as means ± SD, n = 4. 
 
 
A 
 
B 
C D E 
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The cav-1 N-terminal peptides (aa2-20 and 19-40) do not bind the cav-1 C-
terminal peptide (aa161-178) in the absence of NSP4 
 Our laboratory has reported that NSP4 binds to both termini of cav-1 based on 
yeast two-hybrid and peptide binding assays (95).  We verified this finding with 
fluorescence binding assays and further delineated the NSP4 binding site to aa19-40 on 
the N-terminus of cav-1.  Next, we questioned whether both termini of cav-1 bound one 
another and mediated the interaction with NSP4.  We utilized the fluorescence binding 
assay to investigate binding between the N- and C-terminal peptides of cav-1 in an effort 
to explain how NSP4 binds both termini.  The C-terminal C-Cav161-178 peptide was 
labeled with a Cy3-fluorophore and titrated with either the N-Cav2-20 or Cav19-40 peptide.  
Titration of C-Cav161-178 with increasing concentrations of either N-Cav2-20 or Cav19-40 
resulted in no change in fluorescence intensity at 565nm, indicative of a lack of binding 
between the two peptides (Figure 7).  Therefore, the interaction between NSP4 and cav-1 
does not appear to be a result of initial binding between the N- and C-termini of cav-1, 
followed by subsequent binding to NSP4. 
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Figure 7: Direct Fluorescence Binding Assays-N-Cav2-20 or Cav19-40 Peptide with C-Cav161-178 Peptide. 
A-fluorescence spectra of Cy3-C-Cav161-178 titrated with increasing concentrations of Cav19-40 (0-500nM).  
B-C-plots of maximal fluorescence emission (measured at 565nm upon excitation at 550nm) for N-Cav2-20 
(B) and Cav19-40 (C) in the presence of 100nM Cy3-C-Cav161-178.  Insets, linear plots of the binding curve of 
N-Cav2-20 (B) and Cav19-40 (C).   
 
 
We were then interested in investigating the structural interaction between the 
wtNSP4112-140 and N- and C-terminal cav-1 peptides.  While binding assays revealed the 
affinity of each of the peptide-peptide interactions, circular dichroism analysis was 
utilized to analyze the secondary structure of the peptides, individually and following 
peptide-peptide interaction.   
Circular Dichroism Analysis 
Secondary Structure of wtNSP4112-140 
 The structure of the wild-type (wt)-NSP4112-140 peptide was first determined in 
aqueous buffer, (10mM potassium phosphate buffer, pH = 7.4) (Figure 8, dark circles).  
The CD spectrum showed double minima at 208 and 222nm and a single maximum peak 
at 190nm, indicative of -helical secondary structure.  Using the molar ellipticity value at 
A 
B C 
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222nm the -helical content of the wtNSP4112-140 peptide was calculated to be 30.6 ± 
2.4% (Table 4) (125). 
 Trifluoroethanol (TFE) is a hydrophobic solvent that promotes intramolecular 
hydrogen bonding and thus secondary structure formation in peptides.  Therefore, the 
secondary structure of wtNSP4112-140 in 50% TFE was determined by CD (Figure 8, open 
circles).  The CD spectrum showed a dramatic increase in -helix formation of the 
peptide, as evidenced by an increase in both the negative molar ellipticity at 208 and 
222nm and the positive molar ellipticity at 190nm.  The -helical content was calculated 
using the molar ellipticity value at 222nm and determined to be 79.6 ± 4.6%. 
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Figure 8: CD spectra of wtNSP4112-140 in Aqueous Buffer () and 50% TFE ().   
 
 
 Previous CD experiments with the enterotoxic NSP4 peptide (NSP4114-135) 
demonstrate that the -helical content of the peptide increases in the presence of small 
unilamellar vesicles (SUV) containing POPC (a neutral lipid), cholesterol and DOPS (a 
negatively charged lipid) at a 55:35:10 molar ratio (93, 94).  To determine the secondary 
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structural changes that occur in the presence of membranes, the wtNSP4112-140 peptide 
was mixed with SUV model membranes and changes in -helical content were noted by 
CD.   
The CD spectrum of the wtNSP4112-140 peptide in the presence of 1mM SUV 
showed a 2-fold increase in -helix formation over that in aqueous buffer, as evidenced 
by the increase in both the negative molar ellipticity as 208 and 222nm and the positive 
molar ellipticity at 190nm (Figure 9).  The -helical content was calculated using the 
molar ellipticity value at 222nm and determined to be 57.9 ± 1.6% (Table 4).   
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Figure 9: CD Spectra of wtNSP4112-140 in Aqueous Buffer () and in the Presence of 1mM SUV Model 
Membranes (55:35:10, POPC/cholesterol/DOPS) ().   
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Table 4: Percent -helixa of wtNSP4112-140 and Caveolin-1 Peptides in Aqueous 
Buffer, 50% TFE and in the Presence of 1mM SUV. 
 
Peptide: Aqueous Buffer: 50% TFE: 1mM SUVs: 
NSP4112-140 30.6 ± 2.4% 79.6 ± 4.6% 57.9 ± 1.6% 
N-Cav2-20 18.9 ± 2.8% 16.5 ± 0.9% 18.5 ± 1.9% 
Cav19-40 20.7 ± 0.6% 33.4 ± 0.5% 20.5 ± 2.7% 
Cav68-80 23.4 ± 0.9% 24.4 ± 0.8% 21.4 ± 2.0% 
C-Cav161-178 43.4 ± 3.8% 57.4 ± 4.4% 42.5 ± 10.6% 
 
aPercent -helix for each peptide was calculated as described in Materials and Methods. Data is presented 
as mean ± SD, n= 4. 
 
 
Secondary Structure of Caveolin-1 Peptides 
The secondary structures of caveolin-1 peptides corresponding to the N- (N-Cav2-
20 and Cav19-40) and C-termini (C-Cav161-178), as well as to a central region (Cav68-80) of 
the protein, were determined by CD (Table 4).  In aqueous buffer, the -helical content of 
N-Cav2-20, Cav19-40 and Cav68-80 was quite similar, at 18.9%, 20.7% and 23.4% 
respectively (Figure 10, dark circles).  The -helical content of the C-terminal peptide (C-
Cav161-178) was approximately twice (43.4%) that of the N-terminal peptides.  When 
placed in 50% TFE, the -helical content of N-Cav2-20, Cav19-40 and Cav68-80 and C-
Cav161-178 peptides was calculated to be 16.5%, 33.4%, 23.1% and 67.1% respectively 
(Figure 10, open circles).  Only Cav19-40 and C-Cav161-178 showed an increase in -helix 
formation in the presence of 50% TFE.   
When mixed with SUV model membranes, none of the cav-1 peptides 
demonstrated a change in -helix formation over that seen in aqueous buffer (Figure 10, 
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dark triangles; Table 4).  This result was anticipated as none of these peptides 
corresponded to a membrane interacting domain within cav-1. 
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Figure 10: CD Spectra of Caveolin-1 Peptides in Aqueous Buffer (), 50% TFE () and in the 
Presence of 1mM SUV (55:35:10, POPC/cholesterol/DOPS) ().  (A) N-Cav2-20; (B) Cav19-40; (C) 
Cav68-80; (D) C-Cav161-178. 
 
 
 
     Secondary structural changes are observed when wtNSP4112-140 is mixed with C-
Cav161-178  
 Since previous yeast two-hybrid and binding assay data from our laboratory 
demonstrate binding of NSP4 (aa114-135) to both termini of cav-1 (95) and further 
analyses by direct fluorescence binding assays revealed that the N-terminus binds with a 
stronger affinity than the C-terminus, we investigated whether structural changes occur 
upon the interaction between NSP4 and cav-1 peptides.  Each of the cav-1 peptides (N-
Cav2-20, Cav19-40 and C-Cav161-178) was mixed with the wtNSP4112-140 peptide and potential 
A B 
C D 
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secondary structural changes were analyzed by CD.  A peptide corresponding to the 
middle portion of cav-1 (aa68-80) was used as a negative control peptide, as previous 
studies have shown that NSP4 does not interact with this region of cav-1 (45, 95).  
Analysis of the mixing experiments was performed by comparing the spectrum of each 
peptide-peptide mixture (observed) with the sum of the individual spectra of each peptide 
(theoretical).  The -helical content was calculated and statistically significant differences 
(student’s t-test, p<0.05) between the observed and theoretical values indicated a change 
in secondary structure upon mixing of the wtNSP4112-140 and cav-1 peptides.  This change 
in secondary structure was indicative of binding between the two peptides.  A lack of 
secondary structural alterations upon mixture of the peptides, however, did not negate 
binding between the wtNSP4112-140 and cav-1 peptides.  While the direct fluorescence 
binding assays demonstrated that the peptides do in fact interact, the CD experiments 
revealed the extent to which this interaction caused a change in the secondary structure.   
 When each of the caveolin-1 peptides was mixed with wtNSP4112-140 in aqueous 
buffer, only the wtNSP4112-140-C-Cav161-178 mixture showed a significant difference 
between the observed and theoretical values (25.0 ± 1.7% vs. 35.3 ± 1.6%) (Figure 11D; 
Table 4).  No change in secondary structure was observed for the wtNSP4112-140-N-Cav2-
20 (21.7 ± 0.8% vs. 23.6 ± 2.6%), the wtNSP4112-140-Cav19-40 (23.8 ± 1.2% vs. 24.4 ± 
0.6%) or the wtNSP4112-140-Cav68-80 negative control (24.2 ± 0.3% vs. 23.9 ± 0.7%) 
mixtures (Figures 11A-C; Table 5).  Similarly, when each peptide-peptide pair was 
placed in 50% TFE, only the wtNSP4112-140-C-Cav161-178 mixture showed a significant 
change in secondary structure (44.2 ± 10.6% vs. 67.8 ± 3.2%) (Table 5).   
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Figure 11: CD Spectra of wtNSP4112-140-Caveolin-1 Peptide-Peptide Interactions in Aqueous Buffer.  
(A) wtNSP4112-140 + N-Cav2-20; (B) wtNSP4112-140 + Cav19-40; (C) wtNSP4112-140 + Cav68-80; (D) wtNSP4112-140 
+ C-Cav161-178.  (	)-wtNSP4112-140 spectra; (
)-Cav-1 peptide spectra; ()-Theoretical spectra; ()-
Observed spectra. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C D 
  
 45
 
Table 5: Wild-type (wt)NSP4112-140-Caveolin-1 Peptide-Peptide Interactions 
 
 N-Cav2-20  Cav19-40  Cav68-80  C-Cav161-178 
  Observed Theoretical   Observed Theoretical   Observed Theoretical   Observed Theoretical 
Aqueous Buffer 21.7 ± 0.8 23.6 ± 2.6  23.8 ± 1.2 24.4 ± 0.6  24.2 ± 0.3 23.9 ± 0.7  25.0 ± 1.7* 35.3 ± 1.6 
50% TFE 46.3 ± 7.2 47.6 ± 1.8  58.7 ±  7.7 56.3 ± 2.3  45.9 ± 2.8 49.8 ± 1.8  44.2 ± 10.6* 67.8 ± 3.2 
1mM SUV 34.7 ± 6.0 37.7 ± 1.9  37.7 ± 3.6 39.0 ± 2.3  31.3 ± 0.2* 37.5 ± 1.9  51.9 ± 2.4 49.5 ± 6.2 
 
Percent -helical content of wtNSP4112-140 peptide + Caveolin-1 peptides, in aqueous buffer (10mM potassium phosphate buffer), 50% trifluoroethanol (TFE) and 
in the presence of 1mM SUV (55:35:10, POPC/cholesterol/DOPS).  Observed values were compared with theoretical values, and those that were statistically 
significant by a student’s t-test (p<0.05; denoted by an asterisk) were considered structurally altered, indicative of an interaction.  Results are presented as means 
± S.D. (n= 3 or 4).
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Effect of SUV model membranes on the wtNSP4112-140-Caveolin-1 peptide-
peptide interactions 
Since cav-1 is a membrane bound protein, and NSP4 and the NSP4114-135 peptide 
interact with membranes (93), we were interested in whether the presence of membranes 
would result in secondary structural alterations of the NSP4-cav-1 peptide-peptide 
interaction.  To investigate potential secondary structural changes, each wtNSP4112-140-
cav-1 peptide-peptide combination was mixed with lipid vesicles (SUV), and changes in 
structure were observed by CD.   
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Figure 12: CD Spectra of wtNSP4112-140-Caveolin-1 Peptide-Peptide Interactions in the Presence of 
1mM SUV (55:35:10, POPC/cholesterol/DOPS) in Aqueous Buffer.  (A) wtNSP4112-140 + N-Cav2-20; (B) 
wtNSP4112-140 + Cav19-40; (C) wtNSP4112-140 + Cav68-80; (D) wtNSP4112-140 + C-Cav161-178.  (	)-wtNSP4112-140 
spectra; (
)-Cav-1 peptide spectra; ()-Theoretical spectra; ()-Observed spectra. 
C D 
A B 
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For each NSP4-caveolin-1 peptide-peptide mixture, only the wtNSP4112-140 
peptide mixed with the Cav68-80 peptide (negative control) showed a change in -helical 
content in the presence of SUV (31.3 ± 0.2% vs. 37.5 ± 1.9%) (Figure 12C; Table 5).    
Upon investigation of cav-1 topology, it was noted that aa68-80 are located near the 
membrane interacting domain and therefore may account for the observed structural 
changes when combined with NSP4.  While the wtNSP4112-140-C-Cav161-178 peptide pair 
showed the most change in -helical content in aqueous buffer and 50% TFE, the 
presence of SUV model membranes did not result in a significant conformational change 
(observed vs. theoretical values, Table 5).  This observation suggests that the structural 
interaction between wtNSP4112-140 and C-Cav161-178 is not enhanced by the presence of 
model membranes.  
Taken together with the results from the direct fluorescence binding assays, 
wtNSP4112-140 binds Cav19-40 with the strongest affinity, yet this interaction causes no 
significant change in secondary structure conformation.  The observed -helical content 
did not vary from the expected theoretical value, regardless of whether the peptide 
mixture was in aqueous buffer, 50% TFE or mixed with SUV model membranes.  These 
results suggest that the strong binding between wtNSP4112-140 and Cav19-40 requires 
neither a change in structure, nor the presence of lipids, for this peptide-peptide 
interaction to occur. 
In contrast, NSP4112-140 binds C-Cav161-178 with the weakest affinity, yet this 
interaction results in a significant change in -helix formation.  A change in structure 
was noted when the peptide-peptide mixture was in aqueous buffer or 50% TFE.  
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However, the addition of SUV model membranes had no affect on the structural 
interaction between the two peptides. 
Discussion 
 Data from our laboratory show an interaction between NSP4 and the cellular 
protein caveolin-1 (45, 67, 95).    Initial studies delineated the cav-1 binding domain to 
NSP4 residues 114-135 and more recently to three hydrophobic amino acid residues 
within this domain (45, 96).  Additional in vivo yeast two-hybrid analyses and in vitro 
peptide binding assays reveal that NSP4 interacts with cav-1 via both the N- and C-
termini of cav-1 (aa2-31 and 161-178, respectively) (95).  Herein, we confirmed the 
interaction between NSP4 and the N- and C-termini of cav-1 and further delineated the 
NSP4 binding domain within cav-1 through the use of direct fluorescence binding 
assays.  Utilizing an NSP4 peptide (NSP4112-140) which encompasses the amphipathic -
helix and cav-1 binding domain, as well as cav-1 peptides corresponding to the N- (N-
Cav2-20 and Cav19-40) and C- (C-Cav161-178) termini, we ascertained NSP4-cav-1 peptide-
peptide binding affinities.  Results of the peptide-peptide fluorescence binding assays 
showed that the N-terminus of cav-1 has a stronger affinity for NSP4 than the C-
terminus.  Calculation of binding constants (Kd) gave values of 39.55 ± 10.19nM for the 
NSP4112-140-Cav19-40 interaction, 84.60 ± 6.09nM for NSP4112-140-N-Cav2-20 and 216.64 ± 
35.16nM for NSP4112-140-C-Cav161-178.  Through the use of peptides corresponding to 
separate regions of the N-terminus of cav-1, we were able to further define the NSP4 
binding domain within cav-1.  While previous research mapped the NSP4 binding site to 
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aa2-31 of cav-1, the results of our peptide-peptide fluorescence binding assays further 
narrowed this domain to aa19-40.  
 Following conformation of an interaction between NSP4 and both termini of cav-
1, we were interested in analyzing potential secondary structural changes upon peptide-
peptide interaction.  Circular dichroism analysis was utilized to first reveal the structures 
of the peptides in aqueous buffer.  Previous secondary structure analysis of an NSP4 
peptide corresponding to aa114-135 (NSP4114-135) gave an estimation of 37% -helix for 
the peptide (93, 94).  When the secondary structure of the full-length NSP4 protein was 
analyzed, it was found to consist of ~26% -helix (93).  Secondary structure analysis of 
our NSP4 peptide (NSP4112-140) revealed that the peptide contained 30% -helix, which 
is within the range calculated for the enterotoxic peptide and the full-length protein.  
When placed in the presence of SUV model membranes, which mimics a more 
biologically relevant environment, NSP4112-140 demonstrated an increase in -helical 
content.  This increase in -helix formation indicated that the peptide interacts with 
membranes in a similar manner as the NSP4114-135 peptide.   
To date the crystallographic structure of cav-1 has not been resolved; however 
limited secondary structural studies and bioinformatics analyses have provided insight 
into its structure (75, 76).  CD analysis of aa1-101 reveals that the N-terminus contains 
20% -helix, with aa79-96 constituting the -helix portion, while aa1-78 likely lacks 
significant secondary structure.  An additional study, which used a bioinformatics 
approach, found that aa95-101 contains -helix structure, while aa84-94 form two -
strands.  The data presented herein expands on the currently known structural 
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information.  Using peptides corresponding to the extreme N-terminus of cav-1, we 
show that aa2-20 and aa19-40 contain roughly 20% -helix.  Unexpectedly, the extreme 
C-terminus of cav-1 was determined to contain 43% -helix, twice that of the N-
terminus.  This was surprising, as the bioinformatics study predicted that the C-terminus 
contains primarily random secondary structure.    
 Circular dichroism analysis of NSP4-cav-1 peptide-peptide interactions revealed 
that there is no significant change in -helix formation upon binding between NSP4112-
140 and the N-terminal cav-1 peptides (N-Cav2-20 and Cav19-40).  However, a structural 
change was noted upon interaction of NSP4112-140 with C-Cav161-178.  Taken together with 
the binding assays, these results reveal that while the interaction between NSP4112-140 and 
the N-terminal cav-1 peptides occurs with a strong affinity, binding does not require a 
conformational change in secondary structure.  However, the structural change observed 
upon mixture of the NSP4112-140 and C-Cav161-178 peptides likely occurs in order to allow 
the two peptides to weakly interact. 
The addition of SUV model membranes had no effect on the NSP4112-140-cav-1 
peptide-peptide structural interaction with the N- or C-terminal cav-1 peptides.  Hence, 
the secondary structural interaction is not enhanced in the presence of membranes.  A 
statistically significant conformational change was observed, however, for the NSP4112-
140-Cav68-80 mixture when combined with model membranes.  Since aa68-80 are located 
near the N-terminal membrane attachment domain (N-MAD; aa82-101), as well as the 
transmembrane domain (aa102-134) of cav-1, it was postulated that the observed 
conformational change was due to the interaction of Cav68-80 with the membranes.  
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However, when Cav68-80 was mixed with model membranes, in the absence of NSP4112-
140, no change in secondary structure was observed.  Further analysis is needed to 
determine the reason for this conformational change.      
 The interaction of NSP4 with both termini of cav-1 is unique, as most cav-1 
binding proteins interact with the cav-1 scaffolding domain (CSD, aa82-101) (128, 129, 
130).  Since NSP4 (aa112-140) interacts with the N-terminus of cav-1 more strongly 
than the C-terminus, it is possible that the interaction with the C-terminus is transitory.  
NSP4 activates signaling pathways that mobilize Ca2+i, requiring the protein to interact 
with membrane-associated signaling molecules (57).  The weak binding between NSP4 
and the C-terminus of cav-1 may serve to present and/or orient the viral protein for lipid 
interactions.  After NSP4 is properly presented to molecules within the membrane, the 
C-terminus of cav-1 may then quickly disassociate thus allowing NSP4 to carry out its 
biological function(s).  Since the C-terminus of the cav-1 protein is closely associated 
with membranes and does not extend into the cytoplasm to the same extent as the N-
terminus, it likely has less flexibility and/or accessibility for interactions with other 
proteins.  This lack of freedom is another potential explanation for the weak binding 
observed between NSP4 and the C-terminus of cav-1.  
It has been hypothesized that NSP4 is released from RV-infected cells.  Several 
reports support this hypothesis by either showing the release of full-length NSP4 or a C-
terminal fragment (aa112-175) (61, 68) or by demonstrating interactions with 
extracellular proteins (59, 60).  The differential binding of NSP4 to the N- and C-termini 
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of cav-1 therefore may also potentially function in the presentation and transport of 
NSP4 across the cellular membrane.   
What currently remains unknown is how both termini of cav-1 bind to the same 
domain within NSP4.  Results of the fluorescence binding assay show that the N- and C-
termini of cav-1 do not interact.  Therefore, it doesn’t appear that binding of both termini 
to NSP4 is a result of an initial interaction between the N- and C-termini, followed by 
binding to NSP4.  Crystallographic and cross-linking data on NSP4 reveal that aa95-137 
of the enterotoxic protein oligomerizes into a homotetrameric coiled-coil (38, 39, 48).  
Hence, it is likely that the two termini of cav-1 are binding two different molecules of 
NSP4.   
Several reports highlight the use of peptides and the study of peptide-peptide 
interactions as a means of investigating the interactions that occur between full length 
proteins (108, 109, 110, 111).  This study similarly demonstrates the utility of peptides 
for investigating the interaction(s) between two proteins.  Through the use of peptides 
we further delineated the NSP4 binding domain on cav-1, demonstrated differential 
binding of NSP4 to each of the cav-1 termini and revealed that conformational changes 
in secondary structure are not necessary for the interaction between the NSP4 and cav-1 
binding domains.  These data provide additional insight into the relationship between 
NSP4 and cav-1.    
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CHAPTER III 
THE ENTEROTOXIC PEPTIDE AND CAVEOLIN-1 BINDING DOMAINS OF 
THE ROTAVIRUS NON-STRUCTURAL PROTEIN 4 (NSP4) BINDS 
CHOLESTEROL 
 
Overview 
Rotavirus non-structural protein 4 (NSP4), the first described viral enterotoxin, is 
a multi-functional protein with roles in viral morphogenesis, replication and 
pathogenesis.  Our studies reveal NSP4 and the enterotoxic peptide (NSP4114-135) interact 
with model membranes similar in composition and curvature to caveolae and binds the 
N- and C- termini of caveolin-1.  We now report that a NSP4112-140 peptide, which 
encompasses both the previously reported enterotoxic and caveolin-1 binding domains, 
directly interacted with cholesterol.  Mutations within the cholesterol recognition amino 
acid consensus (CRAC) domain were generated and tested for cholesterol binding.  
Binding results suggest the importance of the NSP4 CRAC sequence in cholesterol 
binding. 
Introduction, Results and Discussion 
The Rotavirus (RV) NSP4 protein was the first described viral enterotoxin (3).  
Several studies highlight its role in diarrhea induction in the absence of other viral 
proteins or replication (3, 7, 18, 54, 55, 56, 57, 58).  Exogenous addition of NSP4 causes 
an increase in [Ca2+]i through a phospholipase C-inositol 1,4,5-triphosphate (PLC-IP3) 
mediated pathway (55).  When expressed endogenously, NSP4 mobilizes Ca2+i, through 
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a PLC-independent pathway (57, 62).  It has been hypothesized that NSP4 is released 
from RV infected cells whereupon it binds to neighboring uninfected cells to initiate 
signaling pathways resulting in diarrhea (59, 60).    
We have shown that full-length NSP4 and its enterotoxic peptide, NSP4114-135, 
preferentially interacts with model membranes that are highly curved and rich in anionic 
phospholipids and cholesterol (93, 94).  These membranes closely resemble caveolae, 
which are highly-curved, sphingomyelin- and cholesterol-rich membrane microdomains 
that also contain glycosphingolipids. Caveolae primarily are identified by the presence 
of caveolin-1, although other proteins such as PTRF-Cavin are present (72, 73).  
Additional studies report that NSP4 colocalizes with caveolin-1 in RV-infected cells and 
full-length, fully glycosylated NSP4 has been found in enriched caveolae fractions 
isolated from the plasma membrane (45, 67).  The enterotoxic peptide of NSP4 (aa114-
135) specifically binds to both the N- and C-termini of caveolin-1 (aa2-31 and 161-178, 
respectively) (45, 95).  Since caveolin-1 and caveolae participate in cholesterol transport, 
and NSP4 binds caveolin-1 and traffics to caveolae, we evaluated whether NSP4 directly 
interacts with cholesterol.   
Many cholesterol binding proteins contain a cholesterol recognition amino acid 
consensus (CRAC) domain, which is characterized by the sequence –L/V-(X)(1-5)-Y-
(X)(1-5)-R/K-, where (X)(1-5) represents between one and five unspecified residues (86).  
This sequence was first characterized in the peripheral-type benzodiazepine receptor 
molecule (86).  Numerous proteins involved in cholesterol transport contain this 
sequence, including caveolin-1 (79)  However, the presence of such a sequence does not 
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necessarily indicate an interaction with cholesterol, as this sequence allows for 
variability and likely is not the only requirement for cholesterol binding (131). 
A number of viral proteins have been shown to bind cholesterol.  These include 
the HIV-1 gp41 transmembrane glycoprotein, the influenza M2 protein and the E1 
fusion protein of Semliki Forest virus (132, 133, 134).  Upon analysis of the amino acid 
sequence of RV NSP4, a CRAC motif was noted between amino acids 126/127-133, 
which localized within the amphipathic -helix, enterotoxic peptide and caveolin-1 
binding domain (3, 38, 39, 45).  To determine the extent to which NSP4 binds 
cholesterol and whether the binding occurs within this domain, a panel of synthetic 
peptides overlapping this region (aa112-140)
 
were labeled with a Cy5-fluorophore and 
titrated with cholesterol in a direct fluorescence binding assay.  NSP4112-140 peptides 
containing mutations within the hydrophobic and charged faces of the amphipathic -
helix, and overlapping the hypothesized CRAC domain of NSP4, were synthesized, 
characterized and utilized to assess the importance of specific residues within the CRAC 
domain. Mutations were introduced into the hydrophobic face (NSP4Hydro112-140) and the 
charged face (NSP4AlaAcidic112-140 and NSP4AlaBasic112-140) of the amphipathic -helix of 
NSP4 as indicated in Table 6 (see Supporting Information). 
We hypothesized that the amphipathic -helix of NSP4 contributes to cholesterol 
interaction.  By disrupting the amphipathicity of the CRAC sequence, we directly 
addressed this question.  We also determined the Kd of the interaction to acquire relative 
binding affinities to cholesterol (45, 126). 
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Wt- and mtNSP4112-140 peptides were labeled with a Cy5 fluorescent dye, using 
the Cy5 Mono-reactive dye pack from Amersham Biosciences (Piscataway, NJ), 
according to the manufacturer’s protocol.  To analyze a binding interaction between each 
of the
 
peptides and cholesterol, an increasing quantity of cholesterol (5-35nM) was 
added to 10-20nM of the Cy5-labeled wt- or mtNSP4112-140 peptides in 2mL of phosphate 
buffered saline (pH 7.4).  The Cy5 fluorophore was excited at 649nm and the emission 
spectra were scanned from 655-720nm (see Supporting Information).  Measurements of 
fluorescent intensities (at 665nm) of the Cy5-NSP4-specific
 
peptides in the presence of 
increasing concentrations of cholesterol were corrected for background (Cy5-NSP4-
specific
 
peptides in buffer alone) and plotted as a function of cholesterol concentration. 
In the absence of cholesterol, the Cy5-NSP4112-140 peptide showed maximum 
fluorescence at 665nm (Figure 13).  Upon titration with cholesterol (5-35nM), Cy5-
NSP4112-140 showed a decrease in fluorescence intensity, indicative of an interaction 
(Figure 13B).  A linear reciprocal plot was generated to determine the binding affinity 
(Kd) of cholesterol for NSP4112-140, which was calculated as 7.67 ± 1.49nM.  A control 
peptide (NSP4150-175Ala), corresponding to the C-terminus of NSP4 and lacking the 
CRAC motif, did not demonstrate a change in fluorescence intensity in the presence of 
cholesterol, and therefore lacked binding (Figures 13C and 13D). 
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Figure 13: Cholesterol Directly Binds the NSP4112-140 Peptide.  (A)-Fluorescence spectra of Cy5-
NSP4112-140 titrated with increasing concentrations of cholesterol.  Spectrum 1, 10nM Cy5-NSP4112-140 in 
buffer only. Spectra 2-8, 10nM Cy5-NSP4112-140 in the presence of 5, 10, 15, 20, 25, 20 and 35nM of 
cholesterol, respectively.  (B)-Plot of maximal fluorescence emission (measured at 665nm upon excitation 
at 649nm) for cholesterol in the presence of 10nM Cy5-NSP4112-140.  Inset, linear plot of the binding curve 
of cholesterol.  (C)-Fluorescence spectra of Cy5-NSP4150-175 (negative control) titrated with increasing 
concentrations of cholesterol. (D)-Plot of maximal fluorescence emission (measured at 665nm upon 
excitation at 649nm) for cholesterol in the presence of 10nM Cy5-NSP4150-175. Inset, linear plot of the 
binding curve of cholesterol. 
 
 
Synthetic peptides containing mutations within the amphipathic -helix/CRAC 
motif similarly were examined for cholesterol binding.  Each of the mutant peptides was 
labeled with a Cy5-fluorophore and evaluated for cholesterol binding by the direct 
fluorescence binding assay as before.  When titrated with increasing concentrations of 
cholesterol (5-35nM), the Cy5-NSP4AlaBasic112-140 peptide demonstrated a decrease in 
fluorescent intensity, similar to that seen with wt-NSP4112-140 (Figure 14A).  This change 
in fluorescence was indicative of cholesterol binding and the Kd for this interaction was 
calculated to be 11.49 ± 2.53nM.  The Cy5-NSP4AlaAcidic112-140 peptide also demonstrated 
a change in fluorescence intensity in the presence of cholesterol, although the observed 
change was less than that seen with the NSP4112-140 and NSP4AlaBasic112-140 peptides.  The 
B 
C D 
A 
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calculated Kd value for the NSP4AlaAcidic112-140 interaction was highly variable, suggesting 
that the interaction with cholesterol was weak.   
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Figure 14: Cholesterol Directly Binds to NSP4AlaBasic112-140 and NSP4AlaAcidic112-140, but not 
NSP4Hydro112-140.  (A-B): Fluorescence spectra of Cy5-NSP4AlaBasic112-140 (A) titrated with increasing 
concentrations of cholesterol.  Spectrum 1, 10nM Cy5-NSP4AlaBasic112-140 in buffer only. Spectra 2-8, 10nM 
Cy5-NSP4AlaBasic112-140 in the presence of 5, 10, 15, 20, 25, 20 and 35nM of cholesterol, respectively.  (B-
D): Plot of maximal fluorescence emission (measured at 665nm upon excitation at 649nm) for cholesterol 
in the presence of 10nM Cy5-NSP4AlaBasic112-140 (B), 20nM Cy5-NSP4AlaAcidic112-140 (C) and 10nM Cy5-
NSP4Hydro112-140 (D). Insets, linear plots of the binding curve of cholesterol. 
 
 
 
Distinct from the NSP4AlaBasic112-140 and NSP4AlaAcidic112-140 mutants, the Cy5-
NSP4Hydro112-140 peptide showed no significant change in fluorescent intensity upon 
titration with cholesterol, indicative of a lack of binding (Figure 14D).  The binding 
affinity (Kd) could not be calculated within the tested cholesterol concentration range.  
These assays were then repeated using unlabeled wt- and mtNSP4112-140 peptides and 
fluorescent NBD-cholesterol.  The results from these experiments verified the results 
from the Cy5-labeled peptide experiments (data not shown). 
A B 
C D 
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Taken together, we demonstrated for the first time that a RV NSP4 peptide 
directly interacted with cholesterol and this interaction overlapped the amphipathic -
helix, enterotoxic peptide and caveolin-1 binding domains (aa112-140).  This interaction 
between cholesterol and the NSP4 CRAC sequence has implications for the trafficking 
of NSP4 in RV infected cells.  Abundant data from our laboratory reveal that NSP4 
interacts with caveolin-1 and caveolae (45, 67, 93, 94, 95, unpublished experiments).  
Given that caveolae are involved in de novo cholesterol transport from the ER to the PM 
(76, 80, 87, 135) and caveolin-1 assists in cholesterol transport, contains a CRAC motif 
and binds cholesterol in a 1:1 ratio (79, 88), it is reasonable that caveolin-1 and 
cholesterol function in NSP4 intracellular transport.  NSP4 interacts with caveolin-1, 
encodes a CRAC motif, traffics to the cell surface via an unconventional pathway and as 
we now show, interacts with cholesterol, with a Kd of 7.67 ± 1.49nM.  We also showed 
that the cholesterol-NSP4 interaction was specific to aa112-140.  Based on these results, 
we reasoned that NSP4 also traffics with cholesterol and caveolin-1 from the ER to the 
plasma membrane by an unconventional transport pathway. 
To further evaluate the role of the CRAC sequence in more detail, NSP4112-140 
peptides containing mutations within the CRAC domain, were assessed for cholesterol 
binding.  The NSP4AlaBasic112-140 peptide contains a lysine to alanine mutation within the 
CRAC motif.   Mutation of the lysine 133 residue failed to abolish cholesterol binding, 
as the peptide bound cholesterol with a Kd of 11.49 ± 2.53nM.  However, when 
compared with the wt-NSP4112-140 peptide, the Kd for the NSP4AlaBasic112-140-cholesterol 
interaction is 1.5-fold higher, indicative of a weaker binding affinity.  The 
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NSP4AlaAcidic112-140 peptide contains an aspartic acid to alanine mutation within the CRAC 
domain and demonstrated an even weaker binding affinity to cholesterol with a highly 
variable Kd value.  The observance of a weaker binding affinity for cholesterol indicates 
the importance of the aspartic acid 132 residue.  However, this residue is located within 
a variable position within the CRAC motif and therefore may not be required for 
cholesterol binding.      
Lack of cholesterol binding to the NSP4Hydro112-140 peptide suggests the tyrosine 
131 residue within the amphipathic -helix is important for the NSP4-cholesterol 
interaction.  Another cholesterol binding study on peptides of the CRAC motif of the 
peripheral-type benzodiazepine receptor suggests that the aromatic ring of tyrosine may 
stack with the A ring of cholesterol (136).  Since the NSP4Hydro112-140 peptide contains a 
tyrosine mutation and completely lacks cholesterol binding activity, it is possible that the 
tyrosine residue of NSP4 likewise is important for binding to cholesterol.  Additional 
studies are needed to confirm this hypothesis. 
Together, these results demonstrate that NSP4 binds cholesterol within the 
amphipathic -helix/enterotoxic peptide/caveolin-1 binding domain and implies that the 
tyrosine 131 residue is important for binding.  In addition, the interaction between NSP4 
and cholesterol supports the hypothesis that NSP4 traffics via a cholesterol transport 
pathway in RV infected cells.  This interaction may also be important for enterotoxic 
function as a previous study utilizing a peptide containing a tyrosine mutation 
demonstrated a lack of diarrheagenic function in mouse pups (94).  The interaction of 
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NSP4 with cholesterol adds to the multitude of unique features of NSP4 and helps to 
explain its novel unconventional transport to the plasma membrane and caveolae. 
Supporting Information-Materials and Methods 
Materials 
Cholesterol, Sephadex G-25 and trifluoroethanol (TFE) were purchased from 
Sigma (St. Louis, MO).  Trifluoroacetic acid (TFA), 1-hydroxy-benzotriazole (HOBt) 
and O-Benzotriazole-N,N,N’,N’-tetramethyluronium-hexafluoro-phosphate (HBTU) 
were purchased from American Bioanalytical (Natick, MA).  N,N-diisopropylethylamine 
(DIPEA) and N,N’-diisopropylcarbodiimide (DIPCIDI) were purchased from CreoSalus 
(Louisville, KY).  Thioanisole, ethanedithiol and anisole were purchased from EMD 
chemicals (Gibbstown, NJ). 
Synthesis and Purification of NSP4 Peptides 
All NSP4
 
peptides were synthesized by fluorenylmethoxycarbonyl (Fmoc) solid-
phase chemistry with either 1-hydroxy-benzotriazole (HOBt), O-Benzotriazole-
N,N,N’,N’-tetramethyluronium-hexafluoro-phosphate (HBTU) and N,N-
diisopropylethylamine (DIPEA), or HOBt and N,N’-diisopropylcarbodiimide (DIPCIDI) 
activation using the Model 90 Peptide Synthesizer (Advanced Chemtech; Louisville, 
KY).  Following synthesis, the peptides were cleaved from the solid resin support and all 
side-chain protecting groups removed by addition of Reagent R (90% trifluoroacetic acid 
(TFA), 5% thioanisole, 3% ethanedithiol and 2% anisole).  The peptide/Reagent R 
cleavage mixture was incubated at RT for a maximum of 2 hours with gentle mixing.  
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To separate the peptides from the solid support, the mixture was filtered through 
a sintered glass filter into a 50mL conical tube containing cold diethyl ether in a dry 
ice/ethanol bath.  Following 2-3 rinses of the filter with TFA, the peptide precipitate was 
pelleted by centrifugation at ~300g for 4 minutes.  The supernatant was removed and 
additional cold diethyl ether was added to the peptide pellet.  The mixture was allowed 
to cool in the dry ice/ethanol bath for several minutes before repelleting.  The 
supernatant was removed, more ether added and the step was repeated an additional two 
times.  The crude peptide precipitate was dried under N2, resolubilized in 10% acetic 
acid and lyophilized.   
Each lyophilized crude peptide was resuspended in 5-10% acetic acid and 
purified from organic contaminants and incomplete peptide fragments by gravimetric gel 
filtration chromatography (Sephadex G25 medium).  The eluted peptide was collected 
by void volume (~190mL), lyophilized and further purified by reverse-phase HPLC 
using a reverse phase C4 Delta Pak column (Waters Chromatography Division, Milford, 
MA) or a reverse phase C18 column (Beckman-Coulter, Fullerton, CA).  Peptides were 
purified using a linear gradient of water to acetonitrile over 30-45 minutes.  Eluted peaks 
were lyophilized and characterized by matrix-assisted laser desorption/ionization 
(MALDI) mass spectrometry (Laboratory for Biological Mass Spectrometry, 
Department of Chemistry, Texas A&M University, College Station, TX).  Mass 
chromatograms revealed if the full-length peptide was present, the mass of the peptide 
and the extent of contaminates in the eluted fraction.  Only peptides of ~95% purity were 
used in this study. 
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Direct Peptide-Cholesterol Interactions  
A previously established direct fluorescent binding assay was utilized to 
determine the binding of wt- and mtNSP4112-140 peptides with cholesterol (45, 126).   The 
wt- and mtNSP4112-140 peptides were labeled with a Cy5 fluorescent dye, using the Cy5 
Mono-reactive dye pack from Amersham Biosciences (Piscataway, NJ).  Cy5 labeling of 
the peptide followed the manufacturer’s protocol.  
To analyze a binding interaction between the wt- and mtNSP4112-140 peptides and 
cholesterol, an increasing quantity of cholesterol (5-35nM) was added to 10-20nM of the 
Cy5-labeled wt- or mtNSP4112-140 peptides in 2mL of phosphate buffered saline (pH 7.4).  
Excitation of the Cy5 fluorophore was carried out at 649nm, and the emission spectra 
was scanned from 655-720nm.  Fluorescence emission spectra were obtained at 25ºC 
with a PC1 photon-counting spectrofluorometer (ISS, Inc., Champaign, IL) with 
excitation and emission slit widths of 1.0.  Spectra were corrected for background and 
maximal fluorescence intensities were measured.  Calculation of the dissociation 
constant (Kd) was performed from the titration curves plotted as quenching in peptide 
fluorescence intensity (F0-F, where F0 and F represented the Cy5-NSP4112-140 
fluorescence intensities in the absence and presence of cholesterol, respectively, at each 
titration point) as a function of cholesterol concentration.  A reciprocal plot of 1/(1-
F/Fmax) vs. CL/F/Fmax was used to calculate the Kd value according to the following 
equation: y = bx + yo, where F is the fluorescence intensity at a given concentration of 
ligand, Fmax is the maximal fluorescence obtained and CL is the ligand concentration.  
The slope of the line (b) is equal to 1/Kd.  The sigmoidal curves were also fit to a Hill 
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plot, according to the following equation: y = axb/(cb + xb), where y and x correspond to 
(F0-F) and the ligand concentration at each point, while a, b and c represent the 
maximum binding (Bmax), the number of binding sites (n) and the Kd value, respectively.   
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Table 6: NSP4 Peptides and Cholesterol Binding  
Peptide: Sequence: 
CRAC 
Sequence 
(aa126/127-
133) 
Cholesterol 
Binding: Kd (nM): 
NSP4112-140 MIDKLTTREIEQVELLKRIYDKLTVQTTG (L)LKRIYDK Yes 7.67 ± 1.49nM 
NSP4Hydro112-140 MRDKLTTREIEQKELLKRIDDKLTVQTTG (L)LKRIDDK No N/A 
NSP4AlaAcidic112-140 MIAKLTTREIEQVALLKRIYAKLTVQTTG (L)LKRIYAK No N/A 
NSP4AlaBasic112-140 MIDALTTAEIEQVELLKRIYDALTVQTTG (L)LKRIYDA Yes 11.49 ± 2.53nM 
 NSP4150-175Ala QKNVRTLEEWESGKNPYEPREVTAM N/A No N/A 
 
Mutated amino acids are shown in red.
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CHAPTER IV 
ADDITIONAL DATA, CONCLUSIONS AND FUTURE RESEARCH  
 
Additional Data 
 
Secondary Structure of mtNSP4112-140 Peptides 
The amphipathic -helix (AAH) of NSP4 contains a hydrophobic face and a 
charged face with both acidic and basic charged regions.  Mutational analysis of the AAH 
of NSP4 recently revealed that binding to cav-1 occurs via a hydrophobic interaction 
(96).  However, the extent to which the mutations alter the secondary structure and thus 
affect binding to cav-1 was unknown.  Therefore circular dichroism was utilized to 
investigate changes in the secondary structure as a result of the mutations in the AAH.  
Three peptides encompassing aa112-140 of NSP4 were synthesized that contained 
mutated residues in the hydrophobic (NSP4Hydro112-140), acidic (NSP4AlaAcidic112-140) or 
basic (NSP4AlaBasic112-140) face of the AAH.  The sequences of each of the NSP4 peptides 
are given in Table 7.  NSP4Hydro112-140 contains three charged amino acids (aa113, 124, 
131) that were mutated from the original hydrophobic residues.  NSP4AlaAcidic112-140 and 
NSP4AlaBasic112-140 each contain three alanine residues substituted for negatively charged 
(aa114, 125, 132) and positively charged (aa115, 119, 133) residues, respectively.   
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Table 7: Sequences of wt- and mtNSP4112-140 Peptidesa 
 
Peptide Name: Peptide Sequence (NC): 
NSP4112-140 (aa112-140) MIDKLTTREIEQVELLKRIYDKLTVQTTG 
NSP4Hydro112-140 (aa112-140) MRDKLTTREIEQKELLKRIDDKLTVQTTG 
NSP4Ala Acidic112-140 (aa112-140) MIAKLTTREIEQVALLKRIYAKLTVQTTG 
NSP4Ala Basic112-140 (aa112-140) MIDALTTAEIEQVELLKRIYDALTVQTTG 
 
aAmino acid residues that have been mutated are highlighted in red. 
 
 
Mutations within the hydrophobic face of the amphipathic -helix of NSP4 
alter the secondary structure 
 As shown in Figure 15, the CD spectra of the mutant NSP4 (mtNSP4) peptides in 
aqueous buffer differed from that of the wild-type peptide (Figure 15B-D, dark circles).  
The -helical content was calculated based on the molar ellipticity values at 222nm.  The 
NSP4Hydro112-140 peptide seemed to be most affected by the mutations made in the AAH, 
as the -helical content was determined to be 19.4 ± 2.2% (Table 8).  The mutations 
made in each of the charged faces of the AAH had less of an affect on -helix formation 
within the corresponding peptides.  The -helical content for the NSP4AlaAcidic112-140 and 
NSP4AlaBasic112-140 peptides was determined to be 23.7 ± 0.6% and 26.2 ± 2.9%, 
respectively.   
In the presence of 50% TFE, the -helical secondary structure of each of the 
mutant NSP4 peptides increased 2.5-3 times over that observed in aqueous buffer (Figure 
15B-D, open circles).  As in aqueous buffer, the NSP4Hydro112-140 peptide exhibited less -
helical formation (57.8 ± 0.6%) than the NSP4AlaAcidic112-140 and NSP4AlaBasic112-140 
peptides (73.1 ± 7.3% and 75.3 ± 2.8%, respectively) (Table 8).  Therefore, mutation of  
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hydrophobic residues within the amphipathic -helix/cav-1 binding domain of NSP4 
most negatively affected the -helix forming ability of the peptide.  Mutation of charged 
residues, however, only had a slight affect (NSP4AlaAcidic112-140) or no affect 
(NSP4AlaBasic112-140) on the -helix forming ability of the peptides. 
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Figure 15: CD Spectra of wt- and mtNSP4112-140 Peptides in Aqueous Buffer (	) and 50% TFE (
).  
(A) wtNSP4112-140; (B) NSP4Hydro112-140; (C) NSP4AlaAcidic112-140; (D) NSP4AlaBasic112-140. 
 
 
 
 
 
 
 
 
A 
C 
B 
D 
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Table 8: Percent -helixa of wt- and mtNSP4112-140 Peptides in Aqueous Buffer, 50% 
TFE and in the Presence of 1mM SUV (55:35:10, POPC/cholesterol/DOPS). 
 
Peptide: Aqueous Buffer: 50% TFE: 1mM SUV: 
NSP4112-140 30.6 ± 2.4% 79.6 ± 4.6% 57.9 ± 1.6% 
NSP4Hydro112-140 19.4 ± 2.2% 57.8 ± 0.6% 30.9 ± 0.7% 
NSP4AlaAcidic112-140 23.7 ± 0.6% 73.1 ± 7.3%  36.9 ± 0.7% 
NSP4AlaBasic112-140 26.2 ± 2.9% 75.3 ± 2.8% 49.2 ± 0.5% 
 
aData is presented as mean ± SD, n= 4. 
 
 
 
To determine how the mutations within the AAH affect membrane interactions, 
each of the mtNSP4112-140 peptides was mixed with SUV model membranes (55:35:10, 
POPC/cholesterol/DOPS) and changes in -helical content were noted by CD.   
The CD spectrum of the mtNSP4112-140 peptides showed a 1.5-2-fold increase in -
helix formation from that in aqueous buffer (Figure 16).  While -helix formation of the 
mutant peptides increased in the presence of SUV, the calculated content was less than 
that observed with the wtNSP4112-140 peptide in the presence of SUV.  The NSP4AlaBasic112-
140 peptide demonstrated a 2-fold increase in -helix formation in the presence of 
membranes (49.2 ± 0.5%).  The -helical content of the NSP4Hydro112-140 and 
NSP4AlaAcidic112-140 peptides was significantly less than that of wtNSP4112-140, however, 
and was determined to be 30.9 ± 0.7% and 36.9 ± 0.7%, respectively (Table 8).  Thus, 
mutation of residues within the AAH of NSP4 results in decreased -helix formation and 
thus interaction with lipids.  
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Figure 16: CD Spectra of wt- and mtNSP4112-140 Peptides in Aqueous Buffer () and in the Presence 
of 1mM SUV (55:35:10, POPC/cholesterol/DOPS) ().  (A) wtNSP4112-140; (B) NSP4Hydro112-140; (C) 
NSP4AlaAcidic112-140; (D) NSP4AlaBasic112-140. 
 
 
 
Taken together with previous yeast two-hybrid and peptide-binding assay data, 
these peptide secondary structural studies suggest that the structural conformation of 
NSP4 may play a role in cav-1 binding.  Mutation of the hydrophobic face of the AAH of 
NSP4 abolishes binding to cav-1 (96), and results in secondary structural changes in the 
corresponding peptide (NSP4Hydro112-140).  Circular dichroism analysis revealed a 
significant decrease in -helix formation from that of the wtNSP4112-140 peptide.  
Conversely, mutation of the charged face of the AAH resulted in minimal, if any, change 
in the secondary structure of the corresponding peptides (NSP4AlaAcidic112-140 and 
NSP4AlaBasic112-140).  Additional studies that abolish cav-1 binding while maintaining the 
secondary structure are needed to verify the role of conformation in cav-1 binding. 
A B 
C D 
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Mutagenesis of the AAH also had an affect on the structural interactions of the 
mutant peptides with model membranes.  When in the presence of model membranes, 
each of the mutant peptides demonstrated an increase in -helix formation, indicative of 
an interaction.  While the -helical content was shown to increase, it was still less than 
that observed for the wtNSP4112-140 peptide following lipid interaction.  This alteration in 
structure may have potential implications for NSP4 function. 
Diarrhea Induction in Mouse Pups 
To examine the biological relevance (enterotoxic activity) of the mutations made 
in the amphipathic -helix/enterotoxic peptide/caveolin-1 binding domain of NSP4, each 
of the NSP4-specific peptides was tested for diarrhea induction in mouse pups as 
previously described (3, 68).  Briefly, each of the NSP4-specific peptides (200-400nmol) 
was administered by intraperitoneal delivery to 6-10 day old mouse pups.  Prior to 
injection, all purified peptide samples were tested for endotoxin by the Limulus 
Amebocyte Lysate (LAL) test (Associates of Cape Cod, Inc.) according to the 
manufacturer’s protocol, to ensure that samples were endotoxin free.  A value of 0.5 
EU/mL or less was considered acceptable for use in the diarrhea studies.  Mouse pups 
injected with endotoxin free PBS served as a control.  Mouse pups were monitored for 
diarrhea every 2 hours for 12 hours and then at 24 hours post injection.  The severity of 
the diarrhea was scored on a scale of 1 to 4.   
Mutations within the hydrophobic and basic charged faces of the amphipathic 
-helix of NSP4 abolish diarrheagenic activity in mouse pups 
Following injection, both the wt-NSP4112-140 and NSP4AlaAcidic112-140 peptides were 
found to cause diarrhea in 50% and 67% of the mouse pups tested, respectively (Table 9).  
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The NSP4Hydro112-140 and NSP4AlaBasic112-140 peptides, however, did not induce diarrhea in 
any of the mouse pups tested.  While this study merits repeating, these preliminary results 
suggest that residues within both the hydrophobic face and the basic face of the 
amphipathic -helix of NSP4 are important for enterotoxic activity. 
 
 
Table 9: Diarrheagenic Activity of wt- and mtNSP4112-140 Peptides in Mouse Pups. 
 
Peptides % Diarrhea 
NSP4112-140  50% (3/6) 
NSP4Hydro112-140  0% (0/6) 
NSP4AlaAcidic112-140  67% (4/6) 
NSP4AlaBasic112-140  0% (0/6) 
PBS (negative control) 0% (0/4) 
 
 
 
A previous study highlighted the importance of the tyrosine residue in the 
hydrophobic face of the amphipathic -helix (94).  A synthetic peptide in which the 
tyrosine residue was mutated to a lysine was found to lack diarrhea inducing function.  
The current study supports those results and further suggests that the positively charged 
face of the amphipathic -helix may also be important for diarrhea function, possibly 
through a lipid interaction.   
A recent study revealed that the 11 and 21 integrins are receptors for NSP4 
(60).  Binding to these receptors initiates cellular signaling processes (particularly PLC-
mediated signaling) which result in diarrhea in RV infected individuals.  This agrees with 
previous data demonstrating that exogenous addition of NSP4 mobilizes [Ca2+]i from ER 
stores through a phospholipase C-inositol 1,4,5-triphosphate (PLC-IP3) pathway (55).  
While integrin receptor binding was shown to occur via aa114-130, signaling was shown 
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to occur via an interaction between aa131-140 and a separate integrin domain.  Given that 
integrin signaling occurs via aa131-140, and NSP4AlaBasic112-140 has a mutation at aa133 
which abolishes enterotoxic function, it is possible that the lack of diarrhea induction 
seen with this peptide is a result of an inability to initiate signaling through the integrin 
receptor.  Similarly, NSP4Hydro112-140 contains a mutation at aa131, which is within the 
integrin signaling domain, and does not cause diarrhea.  Lack of enterotoxic function 
with this mutant peptide may also be a result of its inability to initiate integrin mediated 
signaling. 
Conclusions and Significance 
 The purpose of this research was to examine and analyze the secondary structural 
and functional interactions between NSP4 and caveolin-1.  Peptides corresponding to the 
amphipathic -helix, enterotoxic peptide and caveolin-1 binding domain of NSP4 (aa112-
140), as well as the N- (aa2-20 and 19-40) and C- (aa161-178) termini of cav-1, were 
synthesized and characterized for the studies involved herein.  Fluorescence binding 
assays demonstrated differential binding of the N- and C-termini of cav-1 to the NSP4112-
140 peptide and were used determined the relative binding affinities (Kd) of these 
interactions.    Utilization of two peptides corresponding to different regions of the N-
terminus of cav-1 allowed for further delineation of the binding domain of NSP4 to aa19-
40 of cav-1.   Subsequent circular dichroism analysis of the NSP4-cav-1 peptide-peptide 
interactions revealed that conformational changes in the secondary structure only occur 
following interaction of NSP4112-140 with C-Cav161-178.  Additionally, NSP4 peptides were 
examined for cholesterol binding utilizing the fluorescence binding assay.  NSP4 was 
shown to bind cholesterol and this interaction occurs via aa112-140.   
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Mutant peptides were synthesized containing mutations within the hydrophobic 
and charged faces of the amphipathic -helix (AAH).  Secondary structural analysis of 
the mutant peptides revealed the extent to which the mutations affected the secondary 
structure of the peptides.  Cholesterol binding and diarrhea induction studies using the 
mutant peptides suggested the importance of hydrophobic and basic amino acid residues 
within the AAH in mediating these functions.   
NSP4112-140 binds the N-terminus of cav-1 with a stronger affinity than the C-
terminus 
While previous research reveals that NSP4 (aa114-135) binds both termini of cav-
1 (45, 95), this study demonstrated differential binding of the cav-1 termini to NSP4.  
NSP4- and cav-1-specific peptides were utilized in a fluorescence binding assay to 
analyze binding between NSP4 and the N- and C-termini of cav-1.  In addition, relative 
binding affinities were determined for these interactions.  Results of the binding assays 
revealed that the NSP4112-140 peptide binds the N-terminus (Kd (aa2-20) = 84.60 ± 
6.09nM; Kd (aa19-40) = 39.55 ± 10.19nM) of cav-1 with a stronger affinity than the C-
terminus (Kd (aa161-178) = 216.64 ± 35.16nM).  Moreover, the NSP4 binding domain 
was further delineated to aa19-40 within the N-terminus of cav-1. 
Secondary structural changes are observed only for the NSP4112-140-C-Cav161-178 
peptide-peptide interaction 
The NSP4112-140 peptide was mixed with each of the cav-1 peptides and secondary 
structural changes were investigated by circular dichroism.  No significant change in 
secondary structure was observed upon interaction of NSP4112-140 with N-Cav2-20, Cav19-40 
or the control peptide, Cav68-80.  However, mixture of NSP4112-140 with C-Cav161-178 
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resulted in a significant change in secondary structure.  Taken together with the results of 
the binding assay, the relatively strong interaction between NSP4112-140 and the N-
terminal cav-1 peptides occurs with no change in secondary structure.  Conversely, the 
relatively weak binding between the NSP4112-140 and C-Cav161-178 peptides results in a 
conformational change in secondary structure. 
NSP4 binds cholesterol within the amphipathic -helix, enterotoxic peptide and 
caveolin-1 binding domains 
 Analysis of the NSP4 sequence revealed a potential cholesterol recognition amino 
acid consensus (CRAC) motif between aa126/127-133, which is located within the 
amphipathic -helix, enterotoxic peptide and cav-1 binding domain.  Therefore, NSP4-
specific peptides were utilized to examine a potential NSP4-cholesterol interaction 
through a direct fluorescence binding assay.  The wtNSP4112-140 peptide bound cholesterol 
with a Kd of 7.67 ± 1.49nM.  A control peptide (NSP4150-175Ala) corresponding to the 
extreme C-terminus of NSP4 and lacking a CRAC motif, did not bind cholesterol.  
Hence, the cholesterol binding domain of NSP4 was determined to be between aa112-
140.  
Mutant NSP4 peptides (NSP4Hydro112-140, NSP4AlaAcidic112-140 and NSP4AlaBasic112-
140), each containing a mutation with the putative CRAC domain, were used to analyze 
the importance of specific residues within the cholesterol binding domain.  The 
NSP4AlaBasic112-140 peptide, containing a lysine to alanine mutation at residue 133, bound 
cholesterol with a Kd of 11.49 ± 2.53nM.  While this mutation resulted in a slight 
decrease in cholesterol binding, the lysine residue within the CRAC domain does not 
appear to be important for cholesterol binding.  Similarly, the NSP4AlaAcidic112-140 peptide, 
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containing an aspartic acid to alanine mutation at residue 132, also bound cholesterol 
with a highly variable Kd value.  The affinity of this interaction was weaker than that 
observed with both the wtNSP4112-140 and NSP4AlaBasic112-140 peptides.  The NSP4Hydro112-
140 peptide, however, demonstrated no interaction with cholesterol.  Since this peptide 
contained a tyrosine to aspartic acid mutation at residue 131, the lack of binding suggests 
the importance of the tyrosine 131 residue in cholesterol binding.   
Mutation of hydrophobic residues within the amphipathic -helix disrupt the 
secondary structure  
 Peptides containing mutated residues within either the hydrophobic (NSP4Hydro112-
140) or charged face (NSP4AlaAcidic112-140 or NSP4AlaBasic112-140) of the amphipathic -helix 
of NSP4 were examined for secondary structural changes by circular dichroism analysis.  
Mutation of hydrophobic residues within the AAH resulted in the most significant 
alterations in the overall structure.  The -helical content for the NSP4Hydro112-140 peptide 
was calculated to be 19.4 ± 2.2%, which is significantly less than that of the wtNSP4112-
140 peptide (30.6 ± 2.4%).  Conversely, mutation of either acidic (NSP4AlaAcidic112-140) or 
basic (NSP4AlaBasic112-140) residues within the AAH had very little or no affect on the 
secondary structure (23.7 ± 0.6% and 26.2 ± 2.9% for NSP4AlaAcidic112-140 and 
NSP4AlaBasic112-140, respectively).  Since previous data reveals that mutation of residues 
within the hydrophobic face abolishes cav-1 binding (96), these results suggest that 
conformation plays a role in the interaction between NSP4 and cav-1.    
 The addition of model membranes resulted in a 1.5-2-fold increase in -helix 
formation for each of the mutant peptides.  However, the total -helical content was less 
than that observed following interaction of the wtNSP4112-140 peptide with membranes.  
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Therefore, mutations within the AAH affect -helix formation, and thus interaction, with 
membranes. 
Hydrophobic and basic amino acid residues within the amphipathic -helix, 
enterotoxic peptide and caveolin-1 binding domains contribute to diarrheagenic 
function 
 Each of the wt- and mtNSP4112-140 peptides was tested for diarrheagenic function 
in mouse pups.  The wtNSP4112-140 peptide caused diarrhea in 50% of the mouse pups 
tested, which agreed with previously published reports (3, 94).  Similarly, the 
NSP4AlaAcidic112-140 peptide caused diarrhea in 67% of the mouse pups tested, indicating 
that acidic residues within the AAH of NSP4 are not important for diarrheagenic 
function.  Both the NSP4Hydro112-140 and NSP4AlaBasic112-140 peptides, however, failed to 
induce diarrhea in mouse pups.  These results suggested that both hydrophobic and basic 
residues within the AAH of NSP4 are involved in diarrhea induction. 
Secondary Structure, caveolin-1, cholesterol and enterotoxic function 
The results of this research provide insight into the relationship among NSP4 
secondary structure, cav-1 binding, cholesterol and diarrheagenic function.   Table 10 
illustrates the relationship between secondary structure and function.  While synthetic 
peptides were used in these studies to further investigate and dissect the various functions 
of NSP4, these findings are postulated to be relevant to the full length protein.   
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Table 10: Relationship Between Secondary Structure and Function, Including Caveolin-1 and Cholesterol Binding and 
Diarrhea Induction, of the wt- and mtNSP4112-140 Peptides. 
 
  % -helix:     
Peptide: Sequence: Buffer 
1mM 
SUV 
(55:35:10) 
Caveolin
-1 
Binding*  
Cholesterol 
Binding 
Diarrhea 
Induction 
NSP4112-140  MIDKLTTREIEQVELLKRIYDKLTVQTTG 30.6% 57.9% yes yes yes 
NSP4Hydro112-140  MRDKLTTREIEQKELLKRIDDKLTVQTTG 19.4% 30.9% no no no 
NSP4AlaAcidic112-140  MIAKLTTREIEQVALLKRIYAKLTVQTTG 23.7% 36.9% yes yes yes 
NSP4AlaBasic112-140  MIDALTTAEIEQVELLKRIYDALTVQTTG 26.2% 49.2% yes yes no 
 
(*tested by yeast two-hybrid (96))
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These data indicate that the hydrophobic face of the amphipathic -helix of NSP4 
plays an essential role in binding to cav-1 and inducing diarrhea, as mutation of 
hydrophobic residues abolished both of these functions (96; Chapter IV, this work).  In 
addition, the hydrophobic face, in particular the tyrosine 131 residue, appears to not only 
be important for enterotoxic activity (94) but for cholesterol binding as well.  Secondary 
structural analysis suggests that conformation may also contribute to each of these 
functions.  However, the extent to which the structure influences the function is 
debatable, as mutagenesis affected both the structure and the function.  Additional studies 
in which hydrophobic residues are replaced with residues that maintain the structural 
conformation are needed to provide clarification on this relationship. 
Results from the cholesterol binding and diarrhea induction assays revealed that 
both the wtNSP4112-140 and NSP4AlaAcidic112-140 peptides bind cholesterol and induce 
diarrhea in mouse pups, while the NSP4Hydro112-140 peptide neither binds cholesterol nor 
induces diarrhea.  Since previous yeast two-hybrid data shows that cav-1 binding occurs 
via three hydrophobic residues within the amphipathic -helix of NSP4 (96), these 
studies seem to suggest that both cav-1 and cholesterol binding contribute to 
diarrheagenic function (Table 10).  However, it appears that cav-1 and cholesterol 
binding are not the only requirements.  Circular dichroism analysis of the NSP4AlaBasic112-
140 peptide revealed that mutation of basic residues within the AAH of NSP4 caused no 
significant change in secondary structure over that of the wtNSP4112-140 peptide, nor did 
they affect cholesterol binding.  However, mutation of the basic residues did eliminate 
diarrheagenic function.  Together, these results suggest that enterotoxic function may be 
dependant on the interaction of NSP4 with a molecule other than cav-1 or cholesterol.    
   80   
 
The integrins 11 and 21 were recently shown to be receptors for NSP4 (60).  
The interaction between NSP4 and the integrin receptors initiates PLC-mediated 
signaling which mobilizes Ca2+i and induces diarrhea in mouse pups (60).  Two separate 
domains of NSP4 are involved in binding to the integrins.  The first domain (aa114-130) 
binds the 11 integrin receptor, while the second domain (aa131-140) initiates signaling 
through the 21 domain.  Examination of the NSP4AlaBasic112-140 peptide sequence reveals 
a lysine to alanine mutation at residue 133, which is within the integrin-mediated 
signaling domain (60).  Since this peptide is structurally similar to the wtNSP4112-140 
peptide and similarly bound cholesterol, yet did not induce diarrhea in mouse pups, it is 
likely that diarrheagenic function is associated with integrin receptor interaction more so 
than secondary structure conformation, cav-1 binding or cholesterol interaction.  
Additionally, secondary structural analysis of the NSP4AlaBasic112-140 peptide in the 
presence of model membranes revealed a decrease in -helix formation.  It is possible 
that the modified structural conformation prevents the interaction of certain amino acid 
residues of NSP4 with the signaling domain of the integrin receptor located within the 
membrane.   
Previous reports suggest that NSP4 traffics from the ER to the PM of RV infected 
cells through an association with cav-1 (45, 61, 67).  Since cav-1 binds and transports 
cholesterol from the ER to the PM (76, 79, 80, 87, 135), and NSP4 has been shown to 
bind cholesterol (Chapter III, this work), it is postulated that the NSP4-cav-1-cholesterol 
interaction is for NSP4 trafficking more so than for enterotoxic function.  Figures 17 and 
18 depict two potential models for the intracellular interaction of NSP4 with cav-1 and 
cholesterol.  In the first model (Figure 17), both the N- and C-termini of cav-1, as well as 
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cholesterol, are postulated to interact with three separate hydrophobic amino acid 
residues within the AAH of a single NSP4 monomer.  Yeast two-hybrid data indicates 
that cav-1 binding occurs via three hydrophobic amino acid residues within NSP4 (96), 
while fluorescence binding assays reveal that cholesterol binding likely occurs via an 
interaction with the Y131 residue of NSP4 (Chapter III, this work).   
 
 
        
Figure 17: Model for the Interaction of Caveolin-1 and Cholesterol with a Monomeric Form of NSP4.  
The dotted lines indicate binding of the N- and C-termini of cav-1, as well as cholesterol, to hydrophobic 
amino acid residues within the AAH of NSP4. 
 
 
 
AAH of NSP4 
Cav-1 
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Therefore, it is possible that the N-terminus of cav-1 interacts with one 
hydrophobic residue within the AAH of NSP4, while the C-terminus of cav-1 interacts 
with another hydrophobic residue and cholesterol interacts with the Y131 residue. 
In the second model (Figure 18), both the N- and C-termini of cav-1, as well as 
cholesterol, are postulated to interact with separate monomers of an oligomeric form of 
NSP4.   
 
 
Figure 18: Model for the Interaction of Caveolin-1 and Cholesterol with an Oligomeric Form of 
NSP4.  The dotted lines indicate binding of the N- and C-termini of cav-1, as well as cholesterol, to 
hydrophobic amino acid residues within the AAH of separate monomers of NSP4. 
 
AAH of NSP4 
Cav-1 
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Since crystallographic data reveals that NSP4 oligomerizes into homotetrameric 
forms (39), each terminus of cav-1, as well as cholesterol, likely interacts with 
hydrophobic amino acid residues within the AAH of separate NSP4 monomers.   
Once at the PM, NSP4 interacts with signaling molecules to initiate signaling 
processes that result in fluid mobilization (57, 62).  Recent reports reveal that NSP4 also 
crosses the PM of RV infected cells whereupon it is hypothesized to initiate signaling 
pathways in neighboring uninfected cells (59, 60, 61).  The mechanism by which this 
occurs, however, is currently unknown.  The differential binding observed between NSP4 
and each of the cav-1 termini may serve to position NSP4 at the PM where it can interact 
with the proper signaling molecules and/or lipids.  Once properly aligned at the 
membrane, the C-terminus of cav-1 may dissociate from NSP4, allowing the protein to 
carry out its enterotoxic function(s).  This may explain the observed weak interaction 
between NSP4 and the cav-1 C-terminus. 
What currently remains to be resolved is whether NSP4 accomplishes the above 
mentioned functions through homo-oligomerization with other NSP4 molecules.  In 
regards to this research, it is unknown whether the NSP4 peptides used in these studies 
were in a monomeric or oligomeric form.  Each of the wt- and mtNSP4 peptides utilized 
corresponded to a portion of the amphipathic -helix, oligomerization domain of NSP4.  
An abundance of research shows that this domain is associated with many functions, 
including cav-1 binding (45, 61, 67, 95, 96), enterotoxic function (3), integrin binding 
(60), tubulin binding (43), cholesterol binding (Chapter III, this work) and lipid 
interactions (93, 94).  The association of NSP4 into higher oligomeric forms may explain 
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how one domain is associated with various functions.  Additional research is needed to 
elucidate the role of oligomerization in NSP4 function(s). 
In conclusion, NSP4 enterotoxic function is presumably a result of the careful and 
complex orchestration between oligomerization, caveolin-1 binding, cholesterol binding, 
receptor/integrin binding and lipid interactions.   
Pitfalls 
Proteins, Peptides and Structure/Function Studies 
 Purification of full length NSP4 has proven to be a difficult undertaking.  NSP4 is 
a membrane protein that contains three hydrophobic domains, which consequently make 
purification of the protein somewhat problematic.  Furthermore, secondary structural 
studies require protein stocks of significant purity (>95%).  As anyone familiar with 
protein purification knows, protein purity usually comes at the expense of protein yield.  
Due to the difficulties associated with purifying a membrane protein to reasonable purity 
and yield needed for our studies, the use of synthetic peptides was an acceptable 
alternative, as sufficient quantities could be synthesized, purified and characterized with 
relative ease.    
This research utilized synthetic peptides of the amphipathic -helix, enterotoxic 
peptide, cav-1 binding domain of RV NSP4 to study secondary structural changes as a 
result of interactions with cav-1 peptides and model membranes (small unilamellar 
vesicles, SUV).  Mutations were then incorporated within these domains and changes in 
secondary structure were assessed.  In addition, each of the NSP4 peptides was evaluated 
for cholesterol binding and diarrheagenic function.  The use of peptides for these studies 
has obvious drawbacks, most notably the fact that peptides only represent a small portion 
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of their corresponding protein and may not always display the same structural and 
functional characteristics as the full length protein.  However, several structure-function 
studies highlight the use of peptides as models for full length proteins (108, 109, 110, 
111).  Therefore, it is reasonable to presume that the results obtained with these peptide 
studies are relevant and reflective of the full length NSP4 protein.  
Circular Dichroism and the Analysis of Peptide-Peptide Interactions 
Circular dichroism (CD) has many advantages as a spectroscopic technique for 
studying peptide and protein secondary and tertiary structure.  It is relatively fast and 
easy, requires low sample concentrations and allows researchers to study the native 
structure of peptides or proteins in solution.  Furthermore, CD is a reliable method for 
studying protein-protein or peptide-peptide interactions, as the interaction of a 
protein/peptide with another protein/peptide can result in changes in the overall structure 
following interaction (137).  However, one disadvantage of this technique is that these 
interactions sometimes result in relatively small, if any, changes in the overall structure.  
Therefore, when studying protein-protein or peptide-peptide interactions, CD should be 
only one of several techniques used to indicate or verify an interaction.   
Another disadvantage of CD is that it is a low resolution technique that only 
provides an overall picture of the secondary structure.  While the percentage of -helix, 
-sheet, turns and random coil can be determined, the exact location and arrangement of 
these structures cannot.  Furthermore, when using this technique to study protein-protein 
or peptide-peptide interactions, one cannot determine the contribution of each individual 
protein/peptide to the overall structure.  To obtain more detailed structural information, a 
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high resolution technique, such as nuclear magnetic resonance (NMR) or X-ray 
crystallography should be utilized. 
Currently, there is limited structural data available on NSP4 due to the difficulties 
associated with purifying the full length protein.  Nevertheless, there have been a few X-
ray crystallographic studies, as well as secondary structural studies, performed on the 
AAH domain (aa95-137) (39, 46, 93, 94).  These studies have provided initial insight into 
aspects of NSP4 structure and how it contributes to the function of the viral protein.  
Future research should focus on developing an improved method for NSP4 protein 
purification, such that a sufficient quantity of full length protein can be purified for use in 
additional structural studies.   
 The Interaction between NSP4 and the N- and C-termini of Caveolin-1 
 While this research revealed differential binding between the NSP4112-140 peptide 
and N- and C-terminal peptides of cav-1, it did not determine how both termini of cav-1 
bind to NSP4.  Through the use of a fluorescence binding assay, we determined that the 
N- and C-termini of cav-1 do not bind to each other.  Therefore, the interaction of both 
termini with NSP4 must occur via different amino acid residues, or possibly via different 
molecules of NSP4.   
 Oligomerization of NSP4 
 The peptides used in this research included a portion of the oligomerization 
domain of NSP4; however, whether these peptides oligomerized or aggregated in the 
functional assays was undetermined.  Previous studies on an NSP4114-135 peptide reveal 
that the peptide does not aggregate when used at concentrations between 2-20µM (93).  
Since the wt- and mtNSP4112-140 peptides utilized in this research contained the same 
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sequence as the NSP4114-135 peptide, and were used at concentrations below 20µM, it is 
likely that the peptides were not oligomerizing or aggregating.  However, whether the 
introduction of mutations affected the concentration at which oligomerization occurs for 
the mtNSP4112-140 peptides is unknown.   
Future Research 
 Purify wt- and mtNSP4 and Caveolin-1 Proteins for Structural and 
Functional Studies 
 This research investigated the structure and functions of NSP4, including cav-1 
binding, cholesterol binding and diarrhea induction, using wt- and mt-peptides 
corresponding to the relevant functional domain (aa112-140).  While we postulate that 
the results of our peptide studies are relevant and predictive of what would be observed 
with full length proteins, the structural and functional studies should be verified using 
purified proteins.  Site-directed mutagenesis would allow for the introduction of the 
appropriate mutations within the NSP4 sequence.  Each of the NSP4 proteins would be 
expressed in a yeast expression system, so that large quantities of protein are available for 
purification.  Caveolin-1 would be purified from a cav-1 expressing cell line, such as 
MDCK cells.  A purification method using a combination of techniques, such as HPLC 
and affinity chromatography, would have to be optimized so that the highest possible 
purity is obtained for each of the proteins.  Once purified, the proteins would be utilized 
in structural and functional studies to verify the results observed with the peptide studies.  
Verify and Characterize the NSP4-Cholesterol Interaction 
  While our initial research indicates that RV NSP4 binds cholesterol, additional 
studies are needed to verify and further define this interaction.  There are currently a 
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number of different in vitro assays available to demonstrate cholesterol binding, 
including thin layer chromatography (TLC) and enzyme-linked immunosorbent assays 
(ELISA) (138, 139, 140).  To test for an NSP4-cholesterol interaction via a TLC assay, 
standard lipid samples or lipids extracted from cells would be applied to a TLC plate and 
run in a solvent mixture for lipid separation.  The remainder of the assay would be 
performed similar to a western blot, where the plate is blocked for non-specific binding, 
incubated with NSP4 (either full length protein or a peptide) followed by an anti-NSP4 
primary antibody and a conjugated secondary antibody.  The plate would then be 
developed to determine if NSP4 bound cholesterol.  Performing an ELISA using 
cholesterol coated plates and incubating with either NSP4 protein or peptide would be 
another option for ascertaining cholesterol binding.   
To further define the amino acid residues involved in the interaction of NSP4 with 
cholesterol, NSP4-specific peptides corresponding to only the CRAC motif (aa126/127-
133) could be synthesized and examined for cholesterol binding via TLC or ELISA.  
Mutations could be introduced at different positions within the CRAC motif to 
definitively determine which residues are important for cholesterol interaction. 
 To validate an NSP4-cholesterol interaction in vivo, [H3]photocholesterol, a 
photoactivatable cholesterol analogue, could be utilized to photoaffinity label cholesterol-
interacting proteins in RV-infected cells (133, 141).  Following ultraviolet irradiation, 
which activates photocholesterol crosslinking and labels cholesterol interacting proteins, 
NSP4 would be immunoprecipitated from the cells and evaluated for cholesterol binding 
by SDS-PAGE and fluorography. 
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Determine Whether the Lack of Diarrheagenic Function by the NSP4Hydro112-
140 and NSP4AlaBasic112-140 Peptides is due to a Lack of Integrin Signaling 
 Functional data on the wt- and mtNSP4112-140 peptides revealed that mutation of 
hydrophobic and basic amino acid residues within the AAH of NSP4 eliminates 
diarrheagenic function in mouse pups (Chapter IV this work).  Since both of these 
mutants contain mutations within the integrin signaling domain (60), it is postulated that 
both mutants lack diarrheagenic function as a result of an inability to induce integrin-
mediated signaling.  Therefore, these mutants should be tested for integrin signaling.  Seo 
et al. utilized a C2C12-2 mouse myoblast cell line, which is a model for collagen-
integrin I signaling, to demonstrate that full length NSP4 induces signaling through an 
interaction with an integrin domain (60).  This cell line expresses the 21 integrin.  
Ligand attachment to the integrin induces signaling, which is demonstrated via cell 
spreading (142).  By investigating the attachment of the NSP4Hydro112-140 and 
NSP4AlaBasic112-140 peptides to C2C12-2 cells and examining for cell spreading, we can 
determine if the lack of diarrhea induction by these peptides was a result of an inability to 
induce integrin-mediated signaling.  The NSP4112-140 peptide contains the integrin 
signaling domain and therefore would serve as a positive control.  Bovine serum albumin 
would serve as a negative control. 
Determine the Stoiciometry of the NSP4-Caveolin-1 Interaction   
 Cross-linking and crystallography experiments revealed that RV NSP4 has an 
oligomerization domain that mediates the formation of dimers and tetramers (38, 39, 48).  
The ability of NSP4 to oligomerize is likely important for its function(s), however, 
studies have yet to examine whether the interaction(s) of NSP4 with other molecules 
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occurs via an oligomeric state.  In regards to the interaction with cav-1, the formation of 
NSP4 oligomers may explain how both termini of cav-1 bind the hydrophobic face of the 
viral protein. 
 There are several techniques available for investigating the stoichiometry of 
peptide or protein complexes, including size-exclusion chromatography (SEC), analytical 
ultracentrifugation, laser light scattering (LS) and mass spectroscopy.  While each of 
these methods allows the estimation of the molecular weight of a sample, which can be 
used to determine the stoichiometry of a complex, the best method for absolute 
determination of molecular weight is a combination of SEC and laser light scattering 
(143, 144, 145, 146, 147, 148).  Using SEC and laser light scattering, in combination with 
interferometric refractometry, the stoichiometry of the NSP4-cav-1 complex could be 
determined.  In the case of the NSP4-cav-1 peptide-peptide interaction, the NSP4112-140 
peptide could be mixed with the N- and C-terminal cav-1 peptides (aa19-40 and aa161-
178, respectively) and examined by SEC/LS.  The NSP4-cav-1 complex would first be 
separated from unbound NSP4 and cav-1 peptides by SEC.  Eluted fractions would be 
monitored by both light scattering and refractive index detectors.  The amount of light 
scattered by the samples in the eluted fractions is directly proportional to the product of 
the concentration and molecular mass (147).  While the light scatter would be measured 
by the light scattering detector, the concentration would be measured by the refractive 
index detector.  The data gathered from these two detectors would then be used to 
calculate the absolute molecular weight.  From this calculated value, the stoichiometry of 
the NSP4-cav-1 complex can be determined.  This should reveal whether NSP4 interacts 
with both termini of cav-1 via a monomeric or an oligomeric state.  However, to 
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definitively determine how the NSP4 interacts with both the N- and C-termini of cav-1, 
the structure of the complex should be resolved using x-ray crystallography.  Ideally, this 
experiment should be completed using purified full length NSP4 and cav-1 proteins.
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